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Abstract
Recent years have brought notable progress in the field of IgA nephropathy. Here, we highlight 
important new directions and latest developments, including successful discovery of several 
genetic susceptibility loci, formulation of the multi-hit pathogenesis model that integrates findings 
from studies of galactose-deficient IgA1, anti-glycan response and immune complex-induced 
kidney injury, introduction of the Oxford pathology scoring system, and formalization of the 
Kidney Disease Improving Global Outcomes (KDIGO) consensus treatment guidelines. We focus 
on the latest genetic findings that confirm a strong contribution of inherited factors and explain 
some of the geo-ethnic disparities in disease susceptibility. Most IgA nephropathy susceptibility 
loci discovered to date encode genes involved in the maintenance of the intestinal epithelial barrier 
and response to mucosal pathogens. The concerted pattern of inter-population allelic 
differentiation across all Genome Wide Association Studies (GWAS) loci parallels the disease 
prevalence and correlates with variation in local pathogens, suggesting that multi-locus adaptation 
might have shaped the present-day landscape of IgA nephropathy. Importantly, the “Intestinal 
Immune Network for IgA Production” emerged as one of the new targets for potential therapeutic 
intervention. We place these findings in the context of the multi-hit pathogenesis model and 
existing knowledge of IgA immunobiology. Lastly, we provide our perspective on the existing 
treatment options, discuss areas of clinical uncertainty, and outline ongoing clinical trials and 
translational studies.
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Introduction
Since its description in 1968 1, IgA nephropathy (IgAN) has been recognized as the most 
common form of primary glomerulonephritis and an important cause of chronic kidney 
disease and end stage kidney failure. Recent years have brought remarkable progress in the 
field of IgAN, largely due to increased collaborative efforts that enabled execution of well-
powered clinical and genetic studies. Landmark developments include the discovery of new 
genetic susceptibility loci, formulation of the multi-hit pathogenesis model based on the 
studies of IgA1 O-glycosylation and anti-glycan antibodies, introduction of the Oxford 
pathology scoring system, as well as formalization of IgAN treatment guidelines. In this 
review, we provide an update on these developments, give our perspective on the treatment 
guidelines, outline the remaining areas of uncertainty, and highlight important new 
directions in the field.
The Diagnosis of IgA Nephropathy
IgAN typically affects young adults, but can also occur in children and the elderly. The 
disease has a wide spectrum of clinical symptoms, ranging from asymptomatic microscopic 
hematuria to a more severe course characterized by sustained proteinuria and rapid 
deterioration of renal function. Definitive diagnosis of IgAN requires a kidney biopsy; the 
disease is defined immunohistologically by dominant or co-dominant glomerular deposits of 
IgA 2. According to recent consensus, the IgA should be at least 1+ in intensity 3 and in 
most cases is 2+ or more 4, and involves the glomeruli diffusely. Typically there is obvious 
dominant staining for IgA with weaker and more variable staining for IgG and/or IgM 4. The 
deposits consist predominantly of polymeric IgA of the IgA1 subclass 5. Among 2,249 cases 
of IgAN compiled from 13 published biopsy series, 100% of cases had positivity for IgA, 
43% had positivity for IgG and 54% for IgM 6. The stronger staining for lambda light chain 
than kappa light chain observed in most cases reflects the predominance of IgA1-lambda in 
the circulation 7.
The histologic features of IgAN are diverse and span the gamut seen in most forms of 
immune complex-mediated proliferative glomerulonephritis (Figure 1). These include no or 
minimal abnormalities by light microscopy, mesangial hypercellularity (defined as 4 or 
more mesangial cells per mesangial area in a 3 μm-thick histologic section, Figure 1a), focal 
endocapillary proliferative (involving <50% glomeruli, Figure 1b), diffuse endocapillary 
proliferative (involving ≥50% glomeruli), necrotizing and crescentic lesions, and more 
rarely membranoproliferative patterns of injury 3,8. Red blood cell casts may be associated 
with acute tubular injury (Figure 1h). In the chronic stages, progression to focal or diffuse 
segmental and global glomerulosclerosis 9 with attendant tubular atrophy and interstitial 
fibrosis occurs (Figure 1d and e).
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By electron microscopy, the glomerular deposits in IgAN are primarily localized to the 
mesangium, with variable subendothelial and rare subepithelial deposits in the more severe 
forms. Mesangial deposits tend to cluster beneath the glomerular basement membrane 
reflection over the mesangium, a location referred to as paramesangial (Figure 1i). The 
glomerular basement membranes may manifest focal thinning, rupture and remodeling, 
which present sources for hematuria.
Henoch-Schönlein purpura nephritis (HSPN) is a systemic form of IgA vasculitis (IgAV) 
with renal manifestations that occurs predominantly in the pediatric age group 10. This 
disease typically manifests with a tetrad of palpable purpura, arthralgia, abdominal pain, and 
renal disease. Although HSPN is frequently self-limiting in children, persistent proteinuria 
and chronic or progressive renal dysfunction are often observed in adult cases 11. The renal 
disease has a similar histologic spectrum as IgA nephropathy, but with greater frequency of 
severe lesions such as glomerular necrosis and crescents (Figure 1g) 12. Correspondingly, 
HSPN has a higher frequency of glomerular staining for fibrin than IgAN, but with an 
otherwise similar immunofluorescence profile.
Heuristic classification systems applied to IgAN in the past, including those by Lee et al. 13 
and Haas et al. 8, were based on the pattern and severity of the proliferative and sclerosing 
lesions, similar to the WHO classification of lupus nephritis. The Oxford IgAN 
classification, devised by a working group of over 40 nephrologists and pathologists 
representing the International IgA Nephropathy Network and the Renal Pathology Society, 
is unique as the first evidence-based schema 3,14. It sought to identify reproducible 
histologic features that predict progression in a large disease cohort with known outcomes, 
and thus represents a scoring system, not a comprehensive classification. The discovery 
cohort included 265 cases of IgAN from Europe, North America and Asia, of which 78% 
were adults. Because the study excluded cases with proteinuria of <0.5 g/day, initial eGFR 
of <30 mL/min per 1.73 m2 and progression to ESRD within 12 months of biopsy, patients 
with very mild disease, rapidly progressive glomerulonephritis, and advanced chronic 
disease were underrepresented 14. Three reproducible histologic features correlated 
independently with both the rate of renal functional decline and renal survival endpoints 
(defined as ≥ 50% reduction in eGFR or ESRD), namely diffuse mesangial hypercellularity 
(M), segmental glomerulosclerosis (S) and tubular atrophy/interstitial fibrosis involving 
>25% of the cortical area (T) 3. Tubular atrophy/interstitial fibrosis involving >50% (versus 
26–50%) of the cortex was associated with even worse outcomes. Endocapillary 
hypercellularity (E) was associated with response to immunosuppressive therapy. The 
MEST score applies the designations M0 or M1 for mesangial hypercellularity involving 
≤50% or >50% of glomeruli, respectively; E0 or E1 for endocapillary hypercellularity in 0 
versus at least 1 glomerulus, S0 or S1 for segmental sclerosis in 0 versus at least 1 
glomerulus, and T0, T1 and T2 for tubular atrophy/interstitial fibrosis involving ≤25%, 26–
50%, and >50% of the cortical area, respectively 3. The major limitation of the Oxford 
system is that the study design constrained its ability to fully address the impact of crescents 
and specific immunofluorescence features, such as the presence of peripheral capillary wall 
deposits of IgA and co-deposits of IgG.
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A number of studies have attempted to validate the predictive value of the MEST lesions in 
independent cohorts from North America 15,16, Europe 17–20 and Asia 21–29, including 
pediatric cases 30,31. These studies have generally confirmed the predictive value of various 
components by univariate and multivariate analyses, but with some differences 32,33. The 
largest meta-analysis based on 16 retrospective cohort studies and involving a total of 3,893 
IgAN cases validated the predictive utility of the M, S, and T lesions, but did not confirm 
the prognostic value of the E score 33. While the E score exhibited some of the weakest and 
most heterogeneous associations with disease progression, the T score was consistently the 
most significant predictor of poor renal outcomes across all cohorts. In addition, five of 16 
studies (4 Asian and 1 European with a total of 1,487 patients) examined the association of 
crescents with clinical outcomes; meta-analysis of these studies showed that the C score 
(defined as presence of any crescents) was strongly associated with progression to kidney 
failure 33. Lastly, the recently published VALIGA study of 1,147 patients from 13 European 
countries (not included in the above meta-analysis) provided an independent validation of 
the predictive value of the M, S and T lesions across a broader spectrum of the disease 31. 
The E score, again, was not associated with outcomes. However, the relationship between 
some variables, such as the E score, and clinical outcomes might have been confounded by 
immunosuppressive treatment exposure, since all of the published validation studies have 
been based on retrospective observational data.
In summary, the Oxford scoring system represents an important step toward improved 
prognostication and standardization of diagnosis, but further refinements of the score may be 
needed to enhance its prognostic utility. A more definitive assessment of the scoring system 
would require a sizable randomized controlled trial in which decisions regarding therapy are 
not made on the basis of pathology. The TESTING study (see below) may present a unique 
opportunity to validate and refine this scoring system while removing inherent therapeutic 
biases.
The Epidemiology of IgA Nephropathy
Because the diagnosis of IgAN requires a kidney biopsy, the exact disease prevalence 
remains difficult to establish. The prevalence of mesangial IgA deposits assessed in 
necropsy studies is surprisingly high, ranging from 4% to 16% depending on the population 
studied 34–36. Similarly, the frequency of IgA deposition in protocol biopsies of living or 
cadaveric donor kidneys is reported to be as high as 16% in Japan 37. These studies suggest 
that subclinical IgA deposition is common and may be more prevalent in East Asian 
populations.
Another commonly reported metric of IgAN occurrence is a relative frequency of IgAN 
among all cases of primary glomerulonephritis in a biopsy registry. Depending on the 
geographic region, this number tends to be highly variable, ranging from 5% in the Middle 
East38,39, 10–35% across Europe40–44 and up to 50% in Japan and China45,46. This metric, 
however, can be affected by disparities in local biopsy practices47 and local incidence of 
other glomerular diseases. An alternate approach to estimating the incidence of IgAN is to 
use data from national ESRD registries. These data still do not reflect true incidence as only 
the patients with progressive disease are captured. A subset of patients with “hypertension” 
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as the cause of ESRD may also represent patients with IgAN who never underwent kidney 
biopsy. In the US, depending on the state of residence, the incidence of ESRD due to IgAN 
ranges from 18 to 264 cases per million population (USRDS 2009) 48. The high level of 
variability between states may be attributable to regional differences in racial/ethnic 
composition and accessibility to healthcare, but it may also reflect a general lack of 
consensus among clinicians on the utility of biopsy in specific clinical settings, resulting in 
high degree of regional disparities in biopsy practices even within the US.
Despite these limitations, some important prevalence patterns have clearly emerged 49. Most 
notably, there is a clear West-to-East prevalence gradient, with the disease being most 
common in East Asia (32–54% of primary GN in China 50 and Japan 51) compared to 
European countries (10–35% of primary GN) 41,42,44,52–63. Similar trends are observed 
when the incidence of ESRD due to IgAN is compared between ethnicities in the US. Asian-
Americans have a 4-fold higher ESRD incidence due to IgAN compared to European-
Americans, and a 7-fold higher incidence compared to African-Americans, further 
supporting a substantial role of genetic factors (USRDS data, 2009) 48. Additionally, a more 
subtle South-to-North prevalence gradient has also been described within Europe; Northern 
Europeans have up to 2.4-fold increased risk of ESRD due to IgAN compared to Southern 
Europeans 48. Lastly, IgAN occurrence has unequal gender distribution. In Europe and 
North America, the disease generally affects males more frequently than females, with male-
to-female ratio as high as 3:1 in Europeans 64,65. In contrast, this ratio approximates 1:1 in 
East Asia 66–68, a pattern that may be shaped by differences in ancestry or local 
environments. These geographic differences also suggest that our existing definition of 
IgAN may encompass a number of distinct disease entities with differential distribution 
between Europe and Asia. Improved sub-classification of IgAN based on the underlying 
disease mechanism rather than descriptive pathology represents perhaps one of the greatest 
challenges for the IgAN research community. In this respect, some of the notable progress 
comes from genetic studies.
The Genetics of IgA Nephropathy
Multiple studies have recognized familial aggregation of IgAN 69–74. In most cases, the 
inheritance is suggestive of autosomal dominant pattern with variable penetrance; however, 
other more complex genetic models are also plausible. Although no large twin studies have 
been performed to formally estimate the heritability of IgAN, several cases of disease 
concordance in identical twins have been reported 75–77. The blood relatives of patients 
affected by IgAN also appear to be at a higher risk of urinary abnormalities 78 and have 
higher levels of galactose-deficient IgA1 79,80.
The first successful application of genome-wide linkage analysis to IgAN families identified 
the significant linkage peak on chromosome 6p22–23 under an autosomal dominant 
inheritance 81. Follow-up linkage studies reported additional suggestive peaks at several 
other loci, providing evidence for significant locus heterogeneity 73,82. Confirmation of 
these loci in the setting of heterogeneity represents a major challenge; if each family carries 
a unique molecular defect in a different gene, hundreds of families will not suffice to 
provide linkage replication. Newer approaches using next generation sequencing face the 
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same limitation – considering significant genetic heterogeneity, finding an independent 
segregating mutation may require sequencing of thousands of probands. For this reason, the 
discovery of rare variants underlying familial IgAN has been challenging, and no causal 
mutations have been identified to date.
Genome-wide association studies (GWAS) represent an alternative approach to genetically 
complex traits, such as IgAN. In contrast to linkage studies, GWAS offer a powerful tool to 
identify susceptibility variants even in the setting of significant locus heterogeneity. The 
inherent limitations of GWAS include the ability to detect only common (frequency > 1–
5%) variants, which typically exhibit relatively small effects; thus, GWAS tend to explain 
only a relatively small proportion of disease heritability 83. To date, GWAS has been 
successfully applied to IgAN in four large-scale studies that led to the identification of 15 
distinct common risk variants at a genome wide significance (Table 1) 84–87. Cumulatively, 
the 15 new and replicated GWAS loci explain approximately 6–8% of the overall disease 
risk 87.
Although the overall disease risk explained by GWAS is relatively small, the hypothesis-
free approach of GWAS provided novel and unbiased insights into human biology of IgAN. 
Most importantly, GWAS loci highlighted several pathogenic disease pathways and pointed 
to potential new therapeutic targets. The implicated pathways include antigen processing 
and presentation (MHC region), the complement system (CFHR1/3 and ITGAM-ITGAX 
loci), regulation of mucosal IgA production (TNFSF13 and LIF/OSM loci) and innate 
immunity against pathogens (DEFA, CARD9, ITGAM-ITGAX and VAV3 loci). The 
cumulative burden of GWAS risk alleles has a strong inverse relationship with the age at 
disease onset, with up to a 20-year difference between the cases with highest and lowest 
numbers of risk alleles 87. These observations may be clinically relevant and suggest that 
pediatric patients have a different disease pathogenesis compared to a late-onset adult 
disease, and thus may also differ in their responsiveness to specific treatments.
In the geospatial analysis of 6,319 individuals representative of 85 worldwide populations, 
the IgAN genetic risk increases sharply with eastward distance from Africa (Figure 2, top 
panel) 48. This model parallels the known West-to-East gradient in disease prevalence, 
suggesting that variation in frequency of GWAS risk alleles may partially explain the geo-
epidemiology of IgAN (see URL for an online genetic risk calculator). Moreover, higher 
resolution geo-genetic analysis of the European continent revealed additional South-to-
North risk gradient, which subsequently led to the discovery of a parallel trend in disease 
incidence. Similar to IgAN, higher latitude has been associated with increased risk of other 
immune diseases, such as multiple sclerosis, type I diabetes or inflammatory bowel disease, 
all of which share common susceptibility loci with IgAN 88–91. Complex selective pressures 
likely underlie these gradients.
The inter-population differences in genetic risk become even more pronounced for the latest 
set of GWAS loci. Interestingly, the risk alleles with largest effects tend to have the greatest 
population differentiation and contribute most to the observed geo-genetic patterns. For 
example, the ITGAM-ITGAX risk alleles demonstrate nearly complete fixation in East Asian 
populations. Taken together, these findings suggest that local selective pressures might have 
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systematically increased the frequency of risk alleles in some populations through the 
process of multilocus adaptation. In the analysis of different ecological variables that could 
potentially provide a selective pressure that drives this adaptation, the diversity of endemic 
pathogens emerged as one of the strongest predictors of genetic risk. Among different 
pathogen classes, the strongest association was found for local helminth diversity (defined as 
a number of endemic helminthic species infecting humans in a given geographic area). 
Notably, worm infestations have been a major source of morbidity and mortality throughout 
human history, and even today helminthes infect nearly a quarter of the world population 92. 
The enhanced IgA response conferred by GWAS risk alleles is likely protective against 
these pathogens, but it can also explain the known association of mucosal infections as a 
common trigger for IgAN.
In aggregate, these findings gave rise to a novel hypothesis that higher genetic risk of IgAN 
in Asia represents an untoward consequence of protective adaptation to worm infections, the 
process that has likely occurred over thousands of years of human-parasite co-evolution. 
Despite recent amelioration of life conditions, availability of effective anti-helminthic 
therapies, and improvements in healthcare delivery, worm infections are far from being 
eradicated in these regions 92,93. Even in the most developed Asian countries, humans 
continue to be exposed to a high diversity of worm species (Figure 2, bottom panel). 
Moreover, the time scale of recent developments would not have been sufficiently long to 
reverse the effect of genetic adaptation. For example, Japan has some of the largest number 
of helminthic species infecting humans, despite the fact that the overall incidence of 
parasitic infections has declined recently. In parallel, Japanese carry the greatest load of 
IgAN risk alleles (Figure 2, top panel) and consistently have some of the highest metrics of 
IgAN prevalence worldwide. Further studies will be needed to test this intriguing new 
hypothesis.
The Multi-hit Pathogenesis Model
The originally proposed multi-hit pathogenesis model integrates findings from studies of 
galactose-deficient IgA1, anti-glycan response, formation and deposition of IgA1-containing 
immune complexes, and mechanisms of immune complex-mediated tissue injury 94 (Figure 
3). Newer insights arising from GWAS contributed to the refinement of this model 95,96 and 
here we extend the model to incorporate the latest genetic data (Table 1). Abnormalities in 
the production of IgA1, leading to elevated levels of galactose-deficient IgA1 (Gd-IgA1), 
represent the first hit in the model. These IgA1 glycosylation defects have been shown to 
have high heritability 79,80. However, family-based studies also demonstrate that an elevated 
level of Gd-IgA1 alone is not sufficient to produce IgAN and additional co-factors are 
required to trigger the formation of immune complexes 79,80. More recent work suggests that 
elevated Gd-IgA1 elicits an autoimmune response, resulting in generation of anti-glycan 
antibodies that recognize N-acetylgalactosamine epitopes on Gd-IgA1 97. This anti-glycan 
response may represent a second hit in the model. The elevation of both Gd-IgA1 and anti-
glycan antibodies leads to formation of immune complexes (Hit 3), which then deposit in the 
glomerular mesangium. This deposition activates the complement pathway, stimulates 
mesangial cells, and induces secretion of cytokines, chemokines, and extracellular matrix 
proteins resulting in inflammation and fibrosis (Hit 4). While this model likely 
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oversimplifies the sequence of pathogenic events, it provides a conceptual framework for 
focused functional studies and testing of candidate genes.
Defect in the regulation of IgA1 production and glycosylation (Hit 1)
Human IgA molecules are composed of two subclasses: IgA1 and IgA2; IgA1 is the 
predominant form in the circulation of healthy individuals and this subclass is also found in 
circulating immune complexes and mesangial immune deposits of patients with IgAN 98,99. 
The IgA1 molecule has a unique hinge segment between the first and second constant-region 
domains of the heavy chains that is the site of attachment of O-linked glycan moieties.
Multiple studies have shown that IgAN patients have significantly higher levels of 
circulating IgA1 with galactose-deficient O-linked glycans in the hinge region (Gd-IgA1), 
and this defect represents a risk factor for nephritis 99–103 and more rapid progression of 
kidney disease 104. Moreover, serum levels of Gd-IgA1 are highly heritable among the 
relatives of adult patients with IgAN 79 as well as pediatric IgAN and HSP nephritis 80, and 
these findings are reproducible in different ethnicities 105. The enzymatic pathway 
responsible for the elongation of IgA1 glycan chains has been studied extensively: the key 
enzymes include N-acetyl-galactosaminyltransferases-2 and −14 (GalNAc-T2 and GalNAc-
T14), which link N-acetylgalactosamine to Serine or Threonine residues of the hinge region, 
followed by core-1-β1,3-galactosyltransferase-1 (C1GalT1) and its chaperone Cosmc, which 
add galacotose to N-acetylgalactosamine, and a number of sialyltransferases 96,99. 
Interestingly, the pattern of O-glycosylation is normal for IgD in patients with IgAN, 
suggesting that these enzymes may be altered specifically in IgA1-producing cells secondary 
to their aberrant immunoregulation 106. Furthermore, IgA1-secreting cell lines from patients 
with IgAN demonstrated a decrease in C1GalT1 activity and an increase in α-N-
acetylgalactosaminide-α-2,6-sialyltransferase 2 (ST6GalNAc-II) activity, which suggests 
that premature sialylation of N-acetylgalactosamine may be contributing to this defect 107.
The glycosylation defects involve predominantly polymeric IgA1, which is normally 
produced by mucosal IgA1-secreting cells 108. Presently, it is not clear how polymeric Gd-
IgA1 finds its way to the circulation in patients with IgAN. An intriguing possibility is that 
mucosal IgA1-secreting cells may migrate to the bone marrow or other systemic sites and 
that this “mis-trafficking” may occur because of faulty expression of surface homing 
receptors 109–111. An alternative hypothesis is that upon antigenic stimulation of genetically-
predisposed individuals, there is an enhanced mucosal IgA1 response that leads to a “spill-
over” from mucosal sites, leading to increased circulating levels of polymeric Gd-IgA1. 
Clinical associations of macroscopic hematuria coinciding with mucosal infections 
(“synpharyngitic hematuria”) further suggest that enhanced mucosal IgA responsiveness to 
an antigenic challenge triggers IgAN. These hypotheses are not mutually exclusive; 
exaggerated mucosal IgA1 responsiveness may lead to a “spill-over” of polymeric Gd-IgA1 
into the circulation, while overstimulation of IgA1-secreting cells may promote “mis-
trafficking” of these cells.
The interplay between mucosal pathogens and IgA immunity is central to the disease 
process; the inherited propensity for enhanced mucosal IgA production in response to 
microbial antigens represents a common pathway for most of the GWAS loci discovered to 
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date (Figure 4, Table 1). For example, the TNFSF13 locus encodes a proliferation inducing 
ligand (APRIL) involved in T cell-independent generation of IgA-secreting plasma 
cells 112,113. The risk variant is associated with a higher serum IgA levels among IgAN 
cases 86,87. Inactivation of Tnfsf13 in mice produces reduced IgA antibody responses to 
mucosal immunization 114. Conversely, over-expression of B cell activating factor (BAFF), 
a related molecule with overlapping functions and receptors with APRIL, results in 
autoimmune disease with commensal flora-dependent mesangial IgA deposits in mice 115. 
Another GWAS locus on chromosome 22q12 encompasses several genes including the 
cytokine-encoding genes LIF and OSM 85. These cytokines are members of the IL-6 family, 
are expressed in mucosal tissues, and have immunoregulatory properties 116–118. The effects 
of LIF and OSM on mucosal production of IgA have not been well studied, but the IgAN 
risk allele at this locus has previously been associated with protection against Crohn’s 
disease, pointing to its involvement in the regulation of intestinal inflammation 119–121. 
Critically, the IgAN risk allele is also associated with higher serum IgA levels among IgAN 
patients 85,87.
Additional GWAS loci that are likely involved in the regulation of mucosal responses to 
pathogens include the DEFA locus (encoding alpha-defensin antimicrobial peptides) and 
CARD9 locus (encoding a pro-inflammatory adapter molecule implicated in the 
pathogenesis of inflammatory bowel disease and involved in the activation of NFk-B 
signaling), as well as ITGAM-ITGAX locus (encoding leukocyte-specific alpha-integrins 
involved in the process of phagocytosis and regulation of IgA production). There is also a 
large set of suggestive IgAN loci that is dramatically enriched for additional genes 
participating in the “Intestinal Immune Network for IgA Production”, one of the pathways 
curated by the Kyoto Encyclopedia of Genes and Genomes database (Figure 4). This 
includes the IL2RA-IL15RA locus (encoding receptor components for IL2 and IL15), the 
ICOS and ICOSLG loci (encoding inducible T-cell co-stimulatory molecules) and the 
TNFRSF13B locus (encoding TACI, a receptor for both BAFF and APRIL). Genetic 
perturbations to the “Intestinal Immune Network for IgA Production” may also have an 
effect on the composition of the commensal gut microbiome, as suggested by early studies 
showing dramatic differences in fecal microbiota between IgAN cases and healthy 
controls 122.
However, the hypothesis of intestinal IgA over-reactivity may not be so straightforward. For 
example, previous studies demonstrated a reduction in J-chain mRNA expression in 
duodenal IgA plasma cells in patients with IgAN 123 and lack of enhanced human IgA 
response to an immune challenge with mucosal tetanus toxoid immunization 124–126. 
Clearly, additional investigations of intestinal IgA responsiveness in IgAN are needed to 
clarify this issue. Follow-up studies are also needed to test if any of these candidate genes 
also affect the process of IgA1 O-glycosylation. Lastly, newer gene mapping approaches 
that utilize serum Gd-IgA1 levels as a quantitative endophenotype may offer further insights 
into the genetic architecture of this trait 127.
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Anti-glycan antibodies (Hit 2)
The galactose-deficient hinge-region of IgA1 contains N-acetylgalactosamine (GalNac) 
residues with or without terminal sialic acid. Recent data suggest that exposed GalNac may 
represent an epitope recognized by specific anti-glycan antibodies, promoting formation of 
circulating immune complexes 97. Because some bacteria and viruses express GalNac on 
their surfaces, exposure to these pathogens could act as a trigger for the formation of cross-
reacting antibodies. The presence of permissive MHC class II alleles may be required for 
this response. While very attractive, this “molecular mimicry” hypothesis will require 
experimental validation. The formation of immune complexes appears critical for the 
nephritogenic property of Gd-IgA1. In vitro studies of cultured human mesangial cells show 
activation with IgA1-IgG immune complexes, but absence of reactivity to isolated Gd-
IgA1128. Recent clinical studies also suggest that using elevated levels of circulating anti-
glycan antibodies as a disease biomarker outperforms serum Gd-IgA1 levels 129. 
Furthermore, the presence of anti-glycan antibodies correlates with proteinuria 97, more 
severe histopathologic injury 129, and faster progression of kidney disease 130. These 
promising findings now require prospective validation.
Immune complex formation and deposition (Hit 3)
A complex series of molecular interactions that remain poorly characterized lead to the 
formation of circulating immune complexes. Circulating polymeric IgA1-containing 
immune complexes induce cleavage of the extracellular domain of FcαR (CD89), forming 
an IgA1-CD89 complex; mice expressing both human IgA1 and CD89 develop mesangial 
deposition of IgA1 resembling human disease 131. These mice also overexpress 
transglutaminase-2 in the mesangium, while transglutaminase-2-deficient animals are 
protected from IgA1 deposition. Transglutaminase-2 is a multifunctional protein 
ubiquitously expressed in all tissues 132; the protein can be externalized, after which it cross-
links with proteins of the extracellular matrix 133,134, but its role in human disease requires 
further study. Interestingly, one of the newly identified loci contains ITGAM, encoding 
integrin αM that is essential for interactions between CD89 and secretory IgA 135,136, but 
the dissection of its precise role also awaits additional studies. Several other molecules have 
been implicated in immune complex binding by mesangial cells 137, of which transferrin 
receptor (CD71) appears most promising 138–141.
Local activation of inflammatory pathways and the complement system (Hit 4)
Once deposited, IgA1-containing immune complexes stimulate mesangial proliferation and 
local production of cytokines, such as IL-6 and TGF-β142,143. These molecules promote 
inflammatory responses by recruiting leukocytes and promote glomerular and 
tubulointerstitial fibrosis. Furthermore, glomerular inflammation is enhanced by the 
complement system; C3 glomerular staining (Figure 1f) is present in over 90–95% of IgAN 
biopsies 2,4,12. In general, C3 staining tends to be less intense and more granular than the 
staining for IgA. C1q is generally negative (in 90% of cases) with less then 10% of cases 
exhibiting scant C1q staining of low (<1+) mean intensity 4,12. Such positivity for C3 with 
negativity for C1q is consistent with activation of either the lectin or the alternative pathway. 
Lectin pathway activation is further suggested by glomerular staining for C4d in the absence 
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of C1q in approximately 40% of IgAN biopsies 144. Moreover, mesangial deposition of 
mannose-binding lectin (MBL) is reported in 25% of IgAN biopsies 145. All MBL-positive 
cases show glomerular co-deposition of L-ficolin, MBL-associated serine proteases and 
C4d, and these patients exhibit greater mesangial and extracapillary proliferation, 
glomerular sclerosis, interstitial infiltration, and proteinuria.
Support for alternative pathway activation in IgAN comes from GWAS. Inheritance of a 
common deletion in factor H-related genes 1 and 3 (CFHR3,1-del) provides additive 
protection from IgAN 48,85,87. CFHR1 and CFHR3 encode regulatory proteins that promote 
activation of the alternative pathway, likely through a competitive inhibition of factor H 
(FH) 146,147. Recent data suggests that CFHR3,1-del is associated with higher levels of 
circulating FH and lower levels of complement activation split products in IgAN. Higher FH 
levels are also positively associated with circulating C3 and negatively correlated with 
mesangial C3 deposition 148. Interestingly, a similar protective effect of CFHR3,1-del has 
been described for age-related macular degeneration, a common cause of retinal disease 
characterized by increased local overactivity of the alternative pathway 149. In contrast, 
CFHR3,1-del has been associated with increased risk of systemic lupus eryhtematosus and 
atypical hemolytic uremic syndrome 150,151. The mechanisms underlying these opposed 
pleiotropic effects of the deletion are presently not well understood.
The Treatment and Prognosis of IgA Nephropathy
The new Kidney Disease Improving Global Outcomes (KDIGO) clinical practice guidelines 
for glomerulonephritis provide an evidence-based review and appraisal of the literature on 
treating IgAN (Table 2). Because these guidelines have been published recently, we refer 
interested readers to the original publication for detailed discussion of supporting 
evidence 152. Here, we provide a brief synthesis of the recommended treatment plan and 
highlight specific areas of ongoing controversy.
The only KDIGO recommendation in IgAN based on unequivocal evidence is for blood 
pressure control and the use of ACE inhibitors or ARBs 152. A target of <130/80 mm Hg is 
recommended for patients with proteinuria <1 g daily, and <125/75 is recommended for 
patients with proteinuria >1 g daily. Additionally, it is recommended that medication be up-
titrated to achieve <1 g of proteinuria daily. A number of randomized controlled trials 
(RCTs) document reduction of proteinuria and delay of GFR deterioration with this 
treatment 153,154,155,156. However, it remains unclear at what level of proteinuria this 
therapy should be initiated. Moreover, although several small studies suggest a benefit in 
proteinuria reduction with combined ACE inhibition and ARB use 157, there are no data 
showing decreased rate of renal failure or mortality. Given the potential risks of such 
combinations, specifically in older and high-risk cardiovascular populations, the 
combination is generally not advised.
The KDIGO guidelines suggest the use of a 6-month trial of corticosteroids in patients with 
persistent proteinuria of >1g/day despite 3–6 months of optimal supportive care. This 
recommendation is based on three RCTs performed in patients with generally preserved 
renal function 158–161 and a meta-analysis, concluding that steroids reduce kidney disease 
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progression in this setting 162. Presently, it is unclear at what level of reduced renal function 
this therapy becomes futile (i.e. “the point of no return”) and whether patients with lower 
levels of proteinuria should also be treated 163.
For patients with crescents involving over 50% of glomeruli, the outcome is likely to be 
unfavorable 164,165. Most nephrologists treat such patients aggressively with pulse 
solumedrol followed by oral corticosteroids and IV cyclophosphamide 166. Rituximab has 
not yet been used in a significant enough number of patients to be recommended, however, 
data from studies on other crescentic diseases suggest a potential benefit 167,168. Of note, the 
exact definition of crescentic IgAN remains somewhat controversial.
Except for crescentic forms, KDIGO does not recommend a routine use of 
cyclophosphamide in addition to corticosteroids. Similarly, the use of MMF and 
azathioprine are generally not recommended; the data for MMF are inadequate, while 
azathioprine offered no additional benefit in a recent well-designed RCT 169. The benefits of 
other interventions, such as tonsillectomy or oral fish oils, also do not appear convincing 152. 
Overall, the evidence supporting these recommendations is of relatively poor quality.
The publication of KDIGO guidelines made it clear that the effectiveness of the existing 
therapies is limited and targeted treatments, more specific to the pathogenic process in 
IgAN, are still lacking. Despite the recommended treatment approach, IgAN remains a 
progressive disease in up to 50% of individuals 170. Overall, it is estimated that 20–40% of 
IgAN cases develop end stage renal disease (ESRD) within 20 years from the time of 
diagnosis 171,172. In the recent VALIGA cohort of 1,147 European patients, the annual rate 
of eGFR decline was 1.8±7.5 ml/min and ESRD developed in 12% of the patients that were 
followed for an average period of 4.7 years from the time of diagnosis 173. A number of 
retrospective studies pointed to several clinical risk factors for kidney disease progression, 
such as depressed baseline eGFR, low serum albumin and hemoglobin levels, severity of 
proteinuria, and elevated blood pressure at the time of biopsy 172,174–177. New online 
clinical decision support tools are also being developed based on these data (see URL for the 
IgAN Progression Calculator). However, most of the progression studies are based on 
single-center cohorts and rely on retrospective data; well-powered prospective cohort studies 
are needed to validate these findings.
In summary, the prognosis of IgAN is quite variable and the outcome remains difficult to 
predict in individual patients 178. The high level of inter-individual differences in disease 
course and inconsistent response to immunosuppressive therapies provide additional support 
for the hypothesis that our existing diagnostic criteria for IgAN likely encompass a more 
diverse set of disease entities. Further disease sub-classification, perhaps based on genetic 
and biomarker profiles specific to the underlying pathogenic process, is urgently needed to 
improve our treatment strategies.
Future Directions
There is a number of new important studies underway to address some of the most critical 
clinical questions outlined above. The CureGN Study (see URL) is a large prospective 
multicenter study of 2,400 patients with common forms of glomerular disease, including 600 
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patients with IgAN. This cohort will generate data on the natural history of IgAN, and 
provide means for a well-powered prospective validation of novel serum, urine, and tissue 
biomarkers for diagnosis, prognosis, and for tailoring treatments. Additionally, new clinical 
trials will soon clarify the role of immunosuppressive regimens in IgAN. The STOP IgAN 
Study (see URL) is a multicenter RCT of nearly 150 IgAN patients with persistent 
proteinuria of >0.75 g daily despite RAS inhibition and supportive therapy; the patients with 
a GFR of >60 cc/min are randomized to alternate day steroid treatment plus solumedrol 
pulses versus placebo, while those with a GFR of 30–60 cc/min are randomized to a regimen 
of cyclophosphamide for 3 months followed by azathioprine versus placebo. Lastly, the 
newly launched TESTING study will randomize >1,000 patients (proteinuria of >1.0 
gm/day and an eGFR of >20 cc/min) to corticosteroids or placebo and is likely to provide 
definitive data on the utility of systemic glucocorticoids.
Moreover, GWAS findings have already stimulated investigations of promising treatment 
approaches that target the newly implicated pathways. Budesonide, a glucocorticoid locally 
released in the ileocecal region near the Peyer’s patches, is being studied in a larger 
controlled trial after proving successful in a small pilot trial 179. Other promising agents 
include Bortezomib (proteosome inhibitor), Fostamatinib (Syk inhibitor), Blisibimod (BAFF 
inhibitor), and Atacicept (humanized recombinant TACI-IgGFc fusion protein with anti-
APRIL and anti-BAFF activity). In addition, the discovery of the protective effect of 
CFHR1,3-del suggests that pharmacologic suppression of the alternative complement 
pathway may be of potential benefit in IgAN.
Nevertheless, GWAS loci discovered to date explain less then 8% of the disease risk, 
suggesting contributions of additional, yet unidentified, genetic and environmental factors. 
Similar to other autoimmune diseases, IgAN is likely to have a highly complex genetic 
architecture with a large number of contributing risk alleles. For example, recent GWAS for 
inflammatory bowel disease (IBD) defined 193 independent risk loci, explaining over 25% 
of familial risk 121. Similarly, 110 GWAS risk alleles have been identified for multiple 
sclerosis (MS), explaining nearly 30% of sibling recurrence 180. New biology arising from 
these studies allowed for identification of previously unrecognized pathways that are shared 
between different autoimmune disorders, shedding light on the common underlying 
mechanisms that could now be targeted pharmaceutically 181. This is highly relevant to 
IgAN, since many of the IgAN risk alleles have shared effects on the risk of IBD, MS, and 
other autoimmune traits. However, the sample size of the aforementioned IBD or MS studies 
is over 4-fold greater compared to the largest IgAN study. Thus, one could reasonably 
expect to discover more IgAN risk alleles with increased GWAS sample size. In addition, 
fine mapping or re-sequencing of risk loci can identify causal alleles and potentially explain 
a larger proportion of disease risk. Moreover, post-GWAS functional studies of the 
molecular mechanisms underlying the observed genetic effects are needed to effectively 
translate the GWAS findings into clinical applications.
The discovery of rare variants with large effect that underlie familial forms of IgAN would 
also be valuable, because such variants readily demonstrate the consequence of severe gain 
or loss of function, and can inform the therapeutic potential of encoded gene products. 
Moreover, studies of pediatric patients may be especially worthwhile, since early onset of 
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disease is correlated with genetic risk. In this regard, the newly established GIGA-kids 
Study (Genomics of IgA-related disorders in kids Study, see URL) aims to enroll >1,000 
children for genetic, genomic, and biomarker discovery studies in IgAN and HSPN. Lastly, 
the ongoing studies aimed at refining the multi-hit model are likely to define new 
biomarkers and potential therapeutic targets. Integration of this model with additional 
genetic discoveries may finally lead to improved disease classification and novel 
personalized treatment strategies.
Acknowledgments
The authors are supported by the Center for Glomerular Disease at Columbia University. Krzysztof Kiryluk is 
supported by the National Institute of Diabetes and Digestive and Kidney Diseases (NIH/NIDDK) grants K23-
DK090207 and R03-DK099654, and Carl W. Gottschalk Research Scholar Grant from the American Society of 
Nephrology (ASN) Foundation for Kidney Research.
References
1. Berger J, Hinglais N. Intercapillary deposits of IgA-IgG. Journal d’urologie et de nephrologie. 1968; 
74:694–5.
2. Roberts IS. Pathology of IgA nephropathy. Nature reviews Nephrology. 2014; 10:445–54. 
[PubMed: 24861083] 
3. Roberts IS, et al. Working Group of the International Ig ANN, the Renal Pathology S. The Oxford 
classification of IgA nephropathy: pathology definitions, correlations, and reproducibility. Kidney 
international. 2009; 76:546–56. [PubMed: 19571790] 
4. Jennette JC. The immunohistology of IgA nephropathy. American journal of kidney diseases: the 
official journal of the National Kidney Foundation. 1988; 12:348–52. [PubMed: 3142256] 
5. Valentijn RM, Radl J, Haaijman JJ, et al. Circulating and mesangial secretory component-binding 
IgA-1 in primary IgA nephropathy. Kidney international. 1984; 26:760–6. [PubMed: 6441067] 
6. Haas, M. IgA Nephropathy and Henoch-Schonlein Purpura Nephritis. In: Jennette, JCDAVD.; 
Olson, JL.; Silva, FG., editors. Heptinstall’s Pathology of the Kidney. 7. Philadelphia: Lippincott 
Williams & Wilkins; 2015. 
7. Chui SH, Lam CW, Lewis WH, Lai KN. Light-chain ratio of serum IgA1 in IgA nephropathy. 
Journal of clinical immunology. 1991; 11:219–23. [PubMed: 1918269] 
8. Haas M. Histologic subclassification of IgA nephropathy: a clinicopathologic study of 244 cases. 
American journal of kidney diseases: the official journal of the National Kidney Foundation. 1997; 
29:829–42. [PubMed: 9186068] 
9. Hill GS, Karoui KE, Karras A, et al. Focal segmental glomerulosclerosis plays a major role in the 
progression of IgA nephropathy. I. Immunohistochemical studies. Kidney international. 2011; 
79:635–42. [PubMed: 21160460] 
10. Jennette JC, Falk RJ, Bacon PA, et al. 2012 revised International Chapel Hill Consensus 
Conference Nomenclature of Vasculitides. Arthritis and rheumatism. 2013; 65:1–11. [PubMed: 
23045170] 
11. Pillebout E, Thervet E, Hill G, Alberti C, Vanhille P, Nochy D. Henoch-Schonlein Purpura in 
adults: outcome and prognostic factors. J Am Soc Nephrol. 2002; 13:1271–8. [PubMed: 
11961015] 
12. Haas, M. IgA Nephropathy and IgA vasculitis (Henoch-Schonlein Purpura Nephritis). 2015. 
13. Lee SM, Rao VM, Franklin WA, et al. IgA nephropathy: morphologic predictors of progressive 
renal disease. Human pathology. 1982; 13:314–22. [PubMed: 7076216] 
14. Cattran DC, et al. Working Group of the International Ig ANN, the Renal Pathology S. The Oxford 
classification of IgA nephropathy: rationale, clinicopathological correlations, and classification. 
Kidney international. 2009; 76:534–45. [PubMed: 19571791] 
15. Herzenberg AM, Fogo AB, Reich HN, et al. Validation of the Oxford classification of IgA 
nephropathy. Kidney international. 2011; 80:310–7. [PubMed: 21544062] 
Magistroni et al. Page 14
Kidney Int. Author manuscript; available in PMC 2016 May 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
16. Yau T, Korbet SM, Schwartz MM, Cimbaluk DJ. The Oxford classification of IgA nephropathy: a 
retrospective analysis. American journal of nephrology. 2011; 34:435–44. [PubMed: 21968096] 
17. Alamartine E, Sauron C, Laurent B, Sury A, Seffert A, Mariat C. The use of the Oxford 
classification of IgA nephropathy to predict renal survival. Clinical journal of the American 
Society of Nephrology: CJASN. 2011; 6:2384–8. [PubMed: 21885791] 
18. Edstrom Halling S, Soderberg MP, Berg UB. Predictors of outcome in paediatric IgA nephropathy 
with regard to clinical and histopathological variables (Oxford classification). Nephrol Dial 
Transplant. 2012; 27:715–22. [PubMed: 21750154] 
19. El Karoui K, Hill GS, Karras A, et al. Focal segmental glomerulosclerosis plays a major role in the 
progression of IgA nephropathy. II. Light microscopic and clinical studies. Kidney Int. 2011; 
79:643–54. [PubMed: 21178978] 
20. Gutierrez E, Zamora I, Ballarin JA, et al. Long-term outcomes of IgA nephropathy presenting with 
minimal or no proteinuria. J Am Soc Nephrol. 2012; 23:1753–60. [PubMed: 22956820] 
21. Zeng CH, Le W, Ni Z, et al. A multicenter application and evaluation of the oxford classification 
of IgA nephropathy in adult chinese patients. American journal of kidney diseases: the official 
journal of the National Kidney Foundation. 2012; 60:812–20. [PubMed: 22819700] 
22. Katafuchi R, Ninomiya T, Nagata M, Mitsuiki K, Hirakata H. Validation study of oxford 
classification of IgA nephropathy: the significance of extracapillary proliferation. Clinical journal 
of the American Society of Nephrology: CJASN. 2011; 6:2806–13. [PubMed: 22157710] 
23. Kang SH, Choi SR, Park HS, et al. The Oxford classification as a predictor of prognosis in patients 
with IgA nephropathy. Nephrol Dial Transplant. 2012; 27:252–8. [PubMed: 21606384] 
24. Shi SF, Wang SX, Jiang L, et al. Pathologic predictors of renal outcome and therapeutic efficacy in 
IgA nephropathy: validation of the oxford classification. Clinical journal of the American Society 
of Nephrology: CJASN. 2011; 6:2175–84. [PubMed: 21852672] 
25. Shima Y, Nakanishi K, Hama T, et al. Validity of the Oxford classification of IgA nephropathy in 
children. Pediatric nephrology. 2012; 27:783–92. [PubMed: 22134880] 
26. Kataoka H, Ohara M, Shibui K, et al. Overweight and obesity accelerate the progression of IgA 
nephropathy: prognostic utility of a combination of BMI and histopathological parameters. 
Clinical and experimental nephrology. 2012; 16:706–12. [PubMed: 22350469] 
27. Moriyama T, Nakayama K, Iwasaki C, et al. Severity of nephrotic IgA nephropathy according to 
the Oxford classification. International urology and nephrology. 2012; 44:1177–84. [PubMed: 
22231129] 
28. Lee H, Yi SH, Seo MS, et al. Validation of the Oxford classification of IgA nephropathy: a single-
center study in Korean adults. The Korean journal of internal medicine. 2012; 27:293–300. 
[PubMed: 23019394] 
29. Le W, Zeng CH, Liu Z, et al. Validation of the Oxford classification of IgA nephropathy for 
pediatric patients from China. BMC nephrology. 2012; 13:158. [PubMed: 23181565] 
30. Coppo R, et al. Working Group of the International Ig ANN, the Renal Pathology S. The Oxford 
IgA nephropathy clinicopathological classification is valid for children as well as adults. Kidney 
international. 2010; 77:921–7. [PubMed: 20200498] 
31. Coppo R, Troyanov S, Bellur S, et al. Validation of the Oxford classification of IgA nephropathy 
in cohorts with different presentations and treatments. Kidney international. 2014; 86:828–36. 
[PubMed: 24694989] 
32. Haas M, Rastaldi MP, Fervenza FC. Histologic classification of glomerular diseases: 
clinicopathologic correlations, limitations exposed by validation studies, and suggestions for 
modification. Kidney international. 2014; 85:779–93. [PubMed: 24088958] 
33. Lv J, Shi S, Xu D, et al. Evaluation of the Oxford Classification of IgA nephropathy: a systematic 
review and meta-analysis. American journal of kidney diseases: the official journal of the National 
Kidney Foundation. 2013; 62:891–9. [PubMed: 23820066] 
34. Sinniah R. Occurrence of mesangial IgA and IgM deposits in a control necropsy population. 
Journal of clinical pathology. 1983; 36:276–9. [PubMed: 6338054] 
35. Waldherr R, Rambausek M, Duncker WD, Ritz E. Frequency of mesangial IgA deposits in a non-
selected autopsy series. Nephrology, dialysis, transplantation: official publication of the European 
Dialysis and Transplant Association - European Renal Association. 1989; 4:943–6.
Magistroni et al. Page 15
Kidney Int. Author manuscript; available in PMC 2016 May 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
36. Varis J, Rantala I, Pasternack A. Immunofluorescence of immunoglobulins and complement in 
kidneys taken at necropsy. Journal of clinical pathology. 1989; 42:1211–4. [PubMed: 2685055] 
37. Suzuki K, Honda K, Tanabe K, Toma H, Nihei H, Yamaguchi Y. Incidence of latent mesangial 
IgA deposition in renal allograft donors in Japan. Kidney international. 2003; 63:2286–94. 
[PubMed: 12753320] 
38. Demircin G, Delibas A, Bek K, et al. A one-center experience with pediatric percutaneous renal 
biopsy and histopathology in Ankara, Turkey. International urology and nephrology. 2009; 
41:933–9. [PubMed: 18696251] 
39. Monfared A, Khosravi M, Lebadi M, et al. Distribution of renal histopathology in Guilan: a single-
center report. Iranian journal of kidney diseases. 2012; 6:173–7. [PubMed: 22555479] 
40. Berthoux F. Annual incidence of glomerulonephritis in the extended Rhone-Alpes region in 1987–
1988. Presse medicale. 1990; 19:1417.
41. Gesualdo L, Di Palma AM, Morrone LF, Strippoli GF, Schena FP. Italian Immunopathology 
Group ISoN. The Italian experience of the national registry of renal biopsies. Kidney Int. 2004; 
66:890–4. [PubMed: 15327376] 
42. Hanko JB, Mullan RN, O’Rourke DM, McNamee PT, Maxwell AP, Courtney AE. The changing 
pattern of adult primary glomerular disease. Nephrol Dial Transplant. 2009; 24:3050–4. [PubMed: 
19487734] 
43. Schena FP. Survey of the Italian Registry of Renal Biopsies. Frequency of the renal diseases for 7 
consecutive years. The Italian Group of Renal Immunopathology. Nephrology, dialysis, 
transplantation: official publication of the European Dialysis and Transplant Association - 
European Renal Association. 1997; 12:418–26.
44. Kurnatowska I, Jedrzejka D, Malyska A, Wagrowska-Danilewicz M, Danilewicz M, Nowicki M. 
Trends in the incidence of biopsy-proven glomerular diseases in the adult population in central 
Poland in the years 1990–2010. Kidney & blood pressure research. 2012; 35:254–8. [PubMed: 
22327616] 
45. Sugiyama H, Yokoyama H, Sato H, et al. Japan Renal Biopsy Registry: the first nationwide, web-
based, and prospective registry system of renal biopsies in Japan. Clinical and experimental 
nephrology. 2011; 15:493–503. [PubMed: 21437579] 
46. Zhou FD, Zhao MH, Zou WZ, Liu G, Wang H. The changing spectrum of primary glomerular 
diseases within 15 years: a survey of 3331 patients in a single Chinese centre. Nephrology, 
dialysis, transplantation: official publication of the European Dialysis and Transplant Association - 
European Renal Association. 2009; 24:870–6.
47. McQuarrie EP, Mackinnon B, Young B, et al. Centre variation in incidence, indication and 
diagnosis of adult native renal biopsy in Scotland. Nephrol Dial Transplant. 2009; 24:1524–8. 
[PubMed: 19074409] 
48. Kiryluk K, Li Y, Sanna-Cherchi S, et al. Geographic differences in genetic susceptibility to IgA 
nephropathy: GWAS replication study and geospatial risk analysis. PLoS genetics. 2012; 
8:e1002765. [PubMed: 22737082] 
49. Okpechi I, Swanepoel C, Duffield M, et al. Patterns of renal disease in Cape Town South Africa: a 
10-year review of a single-centre renal biopsy database. Nephrology, dialysis, transplantation: 
official publication of the European Dialysis and Transplant Association - European Renal 
Association. 2011; 26:1853–61.
50. Li L. Pathological classification and clinical characteristics of primary glomerulonephritis in 
China: bioptic study of 1001 cases. Zhonghua yi xue za zhi. 1989; 69:20–3. 4. [PubMed: 2758342] 
51. Tojo S, Hatano M, Honda N, et al. Natural history of IgA nephropathy in Japan. Seminars in 
nephrology. 1987; 7:386–8. [PubMed: 3445023] 
52. Abdulmassih Z, Makdassi R, Bove N, et al. Epidemiology of primary glomerulonephritis in 
Picardie. Annales de medecine interne. 1990; 141:129–33. [PubMed: 2353754] 
53. Braun N, Schweisfurth A, Lohofener C, et al. Epidemiology of glomerulonephritis in Northern 
Germany. International urology and nephrology. 2011; 43:1117–26. [PubMed: 21505754] 
54. Browne O, Doyle GD, Campbell E. An immunohistological study of IgA nephropathy and a report 
of its incidence in Ireland. Irish journal of medical science. 1985; 154:461–5. [PubMed: 4093274] 
Magistroni et al. Page 16
Kidney Int. Author manuscript; available in PMC 2016 May 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
55. Carvalho E, do Sameiro Faria M, Nunes JP, Sampaio S, Valbuena C. Renal diseases: a 27-year 
renal biopsy study. Journal of nephrology. 2006; 19:500–7. [PubMed: 17048208] 
56. Fisi V, Mazak I, Degrell P, et al. Histological diagnosis determines complications of percutaneous 
renal biopsy: a single-center experience in 353 patients. Kidney & blood pressure research. 2012; 
35:26–34. [PubMed: 21849796] 
57. Heaf J, Lokkegaard H, Larsen S. The epidemiology and prognosis of glomerulonephritis in 
Denmark 1985–1997. Nephrology, dialysis, transplantation: official publication of the European 
Dialysis and Transplant Association - European Renal Association. 1999; 14:1889–97.
58. Mesquita M, Fosso C, Bakoto Sol E, et al. Renal biopsy findings in Belgium: a retrospective single 
center analysis. Acta clinica Belgica. 2011; 66:104–9. [PubMed: 21630606] 
59. Mustonen J, Pasternack A, Helin H, et al. Circulating immune complexes, the concentration of 
serum IgA and the distribution of HLA antigens in IgA nephropathy. Nephron. 1981; 29:170–5. 
[PubMed: 7329493] 
60. Riispere Z, Ots-Rosenberg M. Occurrence of kidney diseases and patterns of glomerular disease 
based on a 10-year kidney biopsy material: a retrospective single-centre analysis in Estonia. 
Scandinavian journal of urology and nephrology. 2012; 46:389–94. [PubMed: 22725262] 
61. Rivera F, Lopez-Gomez JM, Perez-Garcia R. Spanish Registry of G. Clinicopathologic 
correlations of renal pathology in Spain. Kidney international. 2004; 66:898–904. [PubMed: 
15327378] 
62. Schmekel B, Svalander C, Bucht H, Westberg NG. Mesangial IgA glomerulonephritis in adults. 
Clinical and histopathological observations. Acta medica Scandinavica. 1981; 210:363–72. 
[PubMed: 7039240] 
63. Tiebosch AT, Wolters J, Frederik PF, van der Wiel TW, Zeppenfeldt E, van Breda Vriesman PJ. 
Epidemiology of idiopathic glomerular disease: a prospective study. Kidney international. 1987; 
32:112–6. [PubMed: 3626293] 
64. Radford MG Jr, Donadio JV Jr, Bergstralh EJ, Grande JP. Predicting renal outcome in IgA 
nephropathy. Journal of the American Society of Nephrology: JASN. 1997; 8:199–207. [PubMed: 
9048338] 
65. Knoop T, Vikse BE, Svarstad E, Leh S, Reisaeter AV, Bjorneklett R. Mortality in patients with 
IgA nephropathy. American journal of kidney diseases: the official journal of the National Kidney 
Foundation. 2013; 62:883–90. [PubMed: 23796906] 
66. Feehally J, Cameron JS. IgA nephropathy: progress before and since Berger. American journal of 
kidney diseases: the official journal of the National Kidney Foundation. 2011; 58:310–9. 
[PubMed: 21705126] 
67. Lee H, Hwang JH, Paik JH, et al. Long-term prognosis of clinically early IgA nephropathy is not 
always favorable. BMC nephrology. 2014; 15:94. [PubMed: 24946688] 
68. Chandrika BK. IgA nephropathy in Kerala, India: a retrospective study. Indian journal of 
pathology & microbiology. 2009; 52:14–6. [PubMed: 19136771] 
69. O’Connell PJ, Ibels LS, Thomas MA, Harris M, Eckstein RP. Familial IgA nephropathy: a study of 
renal disease in an Australian aboriginal family. Australian and New Zealand journal of medicine. 
1987; 17:27–33. [PubMed: 3497624] 
70. Levy M. Familial cases of Berger’s disease and anaphylactoid purpura: more frequent than 
previously thought. The American journal of medicine. 1989; 87:246–8. [PubMed: 2757072] 
71. Julian BA, Quiggins PA, Thompson JS, Woodford SY, Gleason K, Wyatt RJ. Familial IgA 
nephropathy. Evidence of an inherited mechanism of disease. The New England journal of 
medicine. 1985; 312:202–8. [PubMed: 3855328] 
72. Scolari F, Amoroso A, Savoldi S, et al. Familial clustering of IgA nephropathy: further evidence in 
an Italian population. American journal of kidney diseases: the official journal of the National 
Kidney Foundation. 1999; 33:857–65. [PubMed: 10213640] 
73. Paterson AD, Liu XQ, Wang K, et al. Genome-wide linkage scan of a large family with IgA 
nephropathy localizes a novel susceptibility locus to chromosome 2q36. Journal of the American 
Society of Nephrology: JASN. 2007; 18:2408–15. [PubMed: 17634434] 
Magistroni et al. Page 17
Kidney Int. Author manuscript; available in PMC 2016 May 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
74. Karnib HH, Sanna-Cherchi S, Zalloua PA, et al. Characterization of a large Lebanese family 
segregating IgA nephropathy. Nephrology, dialysis, transplantation: official publication of the 
European Dialysis and Transplant Association - European Renal Association. 2007; 22:772–7.
75. Masuda J, Shiiki H, Fujii Y, Dohi K, Harada A. Identical twin sisters with IgA nephropathy. Nihon 
Jinzo Gakkai shi. 1996; 38:52–6. [PubMed: 8984224] 
76. Tsuboi N, Kawamura T, Okonogi H, Ishii T, Utsunomiya Y, Hosoya T. Discordant 
clinicopathological features in monozygotic twins with IgA nephropathy. Nephrology, dialysis, 
transplantation: official publication of the European Dialysis and Transplant Association - 
European Renal Association. 2011; 26:4146–8.
77. Ahlmen J, Hedman I, Svalander C. Recurrent IgA-nephropathy in an identical twin transplant. 
Clinical transplants. 1989:297. [PubMed: 2487575] 
78. Schena FP, Scivittaro V, Ranieri E, et al. Abnormalities of the IgA immune system in members of 
unrelated pedigrees from patients with IgA nephropathy. Clinical and experimental immunology. 
1993; 92:139–44. [PubMed: 8467558] 
79. Gharavi AG, Moldoveanu Z, Wyatt RJ, et al. Aberrant IgA1 glycosylation is inherited in familial 
and sporadic IgA nephropathy. Journal of the American Society of Nephrology: JASN. 2008; 
19:1008–14. [PubMed: 18272841] 
80. Kiryluk K, Moldoveanu Z, Sanders JT, et al. Aberrant glycosylation of IgA1 is inherited in both 
pediatric IgA nephropathy and Henoch-Schonlein purpura nephritis. Kidney international. 2011; 
80:79–87. [PubMed: 21326171] 
81. Gharavi AG, Yan Y, Scolari F, et al. IgA nephropathy, the most common cause of 
glomerulonephritis, is linked to 6q22–23. Nature genetics. 2000; 26:354–7. [PubMed: 11062479] 
82. Bisceglia L, Cerullo G, Forabosco P, et al. Genetic heterogeneity in Italian families with IgA 
nephropathy: suggestive linkage for two novel IgA nephropathy loci. American journal of human 
genetics. 2006; 79:1130–4. [PubMed: 17186473] 
83. Maher B. Personal genomes: The case of the missing heritability. Nature. 2008; 456:18–21. 
[PubMed: 18987709] 
84. Feehally J, Farrall M, Boland A, et al. HLA has strongest association with IgA nephropathy in 
genome-wide analysis. Journal of the American Society of Nephrology: JASN. 2010; 21:1791–7. 
[PubMed: 20595679] 
85. Gharavi AG, Kiryluk K, Choi M, et al. Genome-wide association study identifies susceptibility 
loci for IgA nephropathy. Nature genetics. 2011; 43:321–7. [PubMed: 21399633] 
86. Yu XQ, Li M, Zhang H, et al. A genome-wide association study in Han Chinese identifies multiple 
susceptibility loci for IgA nephropathy. Nature genetics. 2012; 44:178–82. [PubMed: 22197929] 
87. Kiryluk K, Li Y, Scolari F, et al. Discovery of new risk loci for IgA nephropathy implicates genes 
involved in immunity against intestinal pathogens. Nature genetics. 2014
88. Shapira Y, Agmon-Levin N, Shoenfeld Y. Defining and analyzing geoepidemiology and human 
autoimmunity. J Autoimmun. 2010; 34:J168–77. [PubMed: 20034761] 
89. Borchers AT, Uibo R, Gershwin ME. The geoepidemiology of type 1 diabetes. Autoimmun Rev. 
2010; 9:A355–65. [PubMed: 19969107] 
90. Milo R, Kahana E. Multiple sclerosis: geoepidemiology, genetics and the environment. 
Autoimmun Rev. 2010; 9:A387–94. [PubMed: 19932200] 
91. Handel AE, Handunnetthi L, Giovannoni G, Ebers GC, Ramagopalan SV. Genetic and 
environmental factors and the distribution of multiple sclerosis in Europe. Eur J Neurol. 2010; 
17:1210–4. [PubMed: 20345929] 
92. Pullan RL, Smith JL, Jasrasaria R, Brooker SJ. Global numbers of infection and disease burden of 
soil transmitted helminth infections in 2010. Parasites & vectors. 2014; 7:37. [PubMed: 24447578] 
93. Barry MA, Simon GG, Mistry N, Hotez PJ. Global trends in neglected tropical disease control and 
elimination: impact on child health. Archives of disease in childhood. 2013; 98:635–41. [PubMed: 
23793132] 
94. Suzuki H, Kiryluk K, Novak J, et al. The pathophysiology of IgA nephropathy. Journal of the 
American Society of Nephrology: JASN. 2011; 22:1795–803. [PubMed: 21949093] 
95. Kiryluk K, Novak J, Gharavi AG. Pathogenesis of immunoglobulin A nephropathy: recent insight 
from genetic studies. Annu Rev Med. 2013; 64:339–56. [PubMed: 23072577] 
Magistroni et al. Page 18
Kidney Int. Author manuscript; available in PMC 2016 May 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
96. Kiryluk K, Novak J. The genetics and immunobiology of IgA nephropathy. The Journal of clinical 
investigation. 2014; 124:2325–32. [PubMed: 24892706] 
97. Suzuki H, Fan R, Zhang Z, et al. Aberrantly glycosylated IgA1 in IgA nephropathy patients is 
recognized by IgG antibodies with restricted heterogeneity. The Journal of clinical investigation. 
2009; 119:1668–77. [PubMed: 19478457] 
98. Pabst O. New concepts in the generation and functions of IgA. Nature reviews Immunology. 2012; 
12:821–32.
99. Mestecky J, Raska M, Julian BA, et al. IgA nephropathy: molecular mechanisms of the disease. 
Annual review of pathology. 2013; 8:217–40.
100. Allen AC, Harper SJ, Feehally J. Galactosylation of N- and O-linked carbohydrate moieties of 
IgA1 and IgG in IgA nephropathy. Clinical and experimental immunology. 1995; 100:470–4. 
[PubMed: 7774058] 
101. Novak J, Julian BA, Tomana M, Mestecky J. IgA glycosylation and IgA immune complexes in 
the pathogenesis of IgA nephropathy. Seminars in nephrology. 2008; 28:78–87. [PubMed: 
18222349] 
102. Hiki Y, Horii A, Iwase H, et al. O-linked oligosaccharide on IgA1 hinge region in IgA 
nephropathy. Fundamental study for precise structure and possible role. Contributions to 
nephrology. 1995; 111:73–84. [PubMed: 7758349] 
103. Moldoveanu Z, Wyatt RJ, Lee JY, et al. Patients with IgA nephropathy have increased serum 
galactose-deficient IgA1 levels. Kidney international. 2007; 71:1148–54. [PubMed: 17342176] 
104. Zhao N, Hou P, Lv J, et al. The level of galactose-deficient IgA1 in the sera of patients with IgA 
nephropathy is associated with disease progression. Kidney international. 2012; 82:790–6. 
[PubMed: 22673888] 
105. Hastings MC, Moldoveanu Z, Julian BA, et al. Galactose-deficient IgA1 in African Americans 
with IgA nephropathy: serum levels and heritability. Clinical journal of the American Society of 
Nephrology: CJASN. 2010; 5:2069–74. [PubMed: 20634323] 
106. Smith AC, de Wolff JF, Molyneux K, Feehally J, Barratt J. O-glycosylation of serum IgD in IgA 
nephropathy. Journal of the American Society of Nephrology: JASN. 2006; 17:1192–9. 
[PubMed: 16510764] 
107. Suzuki H, Moldoveanu Z, Hall S, et al. IgA1-secreting cell lines from patients with IgA 
nephropathy produce aberrantly glycosylated IgA1. The Journal of clinical investigation. 2008; 
118:629–39. [PubMed: 18172551] 
108. Boyd JK, Cheung CK, Molyneux K, Feehally J, Barratt J. An update on the pathogenesis and 
treatment of IgA nephropathy. Kidney international. 2012; 81:833–43. [PubMed: 22318424] 
109. Buren M, Yamashita M, Suzuki Y, Tomino Y, Emancipator SN. Altered expression of 
lymphocyte homing chemokines in the pathogenesis of IgA nephropathy. Contributions to 
nephrology. 2007; 157:50–5. [PubMed: 17495437] 
110. Batra A, Smith AC, Feehally J, Barratt J. T-cell homing receptor expression in IgA nephropathy. 
Nephrology, dialysis, transplantation: official publication of the European Dialysis and 
Transplant Association - European Renal Association. 2007; 22:2540–8.
111. Kennel-De March A, Bene MC, Hurault de Ligny B, Kessler M, Faure GC. Enhanced expression 
of CD31 and CD54 on tonsillar high endothelial venules in IgA nephropathy. Clinical 
immunology and immunopathology. 1997; 84:158–65. [PubMed: 9245547] 
112. Stein JV, Lopez-Fraga M, Elustondo FA, et al. APRIL modulates B and T cell immunity. The 
Journal of clinical investigation. 2002; 109:1587–98. [PubMed: 12070306] 
113. He B, Xu W, Santini PA, et al. Intestinal bacteria trigger T cell-independent immunoglobulin 
A(2) class switching by inducing epithelial-cell secretion of the cytokine APRIL. Immunity. 
2007; 26:812–26. [PubMed: 17570691] 
114. Castigli E, Scott S, Dedeoglu F, et al. Impaired IgA class switching in APRIL-deficient mice. 
Proc Natl Acad Sci U S A. 2004; 101:3903–8. [PubMed: 14988498] 
115. McCarthy DD, Kujawa J, Wilson C, et al. Mice overexpressing BAFF develop a commensal 
flora-dependent, IgA-associated nephropathy. The Journal of clinical investigation. 2011; 
121:3991–4002. [PubMed: 21881212] 
Magistroni et al. Page 19
Kidney Int. Author manuscript; available in PMC 2016 May 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
116. Rockman SP, Demmler K, Roczo N, et al. Expression of interleukin-6, leukemia inhibitory factor 
and their receptors by colonic epithelium and pericryptal fibroblasts. Journal of gastroenterology 
and hepatology. 2001; 16:991–1000. [PubMed: 11595063] 
117. Guimbaud R, Abitbol V, Bertrand V, et al. Leukemia inhibitory factor involvement in human 
ulcerative colitis and its potential role in malignant course. European cytokine network. 1998; 
9:607–12. [PubMed: 9889404] 
118. Esashi E, Ito H, Minehata K, Saito S, Morikawa Y, Miyajima A. Oncostatin M deficiency leads to 
thymic hypoplasia, accumulation of apoptotic thymocytes and glomerulonephritis. European 
journal of immunology. 2009; 39:1664–70. [PubMed: 19384873] 
119. Imielinski M, Baldassano RN, Griffiths A, et al. Common variants at five new loci associated 
with early-onset inflammatory bowel disease. Nature genetics. 2009; 41:1335–40. [PubMed: 
19915574] 
120. Franke A, McGovern DP, Barrett JC, et al. Genome-wide meta-analysis increases to 71 the 
number of confirmed Crohn’s disease susceptibility loci. Nature genetics. 2010; 42:1118–25. 
[PubMed: 21102463] 
121. Jostins L, Ripke S, Weersma RK, et al. Host-microbe interactions have shaped the genetic 
architecture of inflammatory bowel disease. Nature. 2012; 491:119–24. [PubMed: 23128233] 
122. De Angelis M, Montemurno E, Piccolo M, et al. Microbiota and metabolome associated with 
immunoglobulin A nephropathy (IgAN). PloS one. 2014; 9:e99006. [PubMed: 24922509] 
123. Harper SJ, Pringle JH, Wicks AC, et al. Expression of J chain mRNA in duodenal IgA plasma 
cells in IgA nephropathy. Kidney Int. 1994; 45:836–44. [PubMed: 8196286] 
124. Waldo FB. Systemic immune response after mucosal immunization in patients with IgA 
nephropathy. Journal of clinical immunology. 1992; 12:21–6. [PubMed: 1551939] 
125. Layward L, Allen AC, Hattersley JM, Harper SJ, Feehally J. Response to mucosal antigen 
challenge in IgA nephropathy. Experimental nephrology. 1995; 3:300–7. [PubMed: 7583052] 
126. Roodnat JI, de Fijter JW, van Kooten C, Daha MR, van Es LA. Decreased IgA1 response after 
primary oral immunization with live typhoid vaccine in primary IgA nephropathy. Nephrol Dial 
Transplant. 1999; 14:353–9. [PubMed: 10069188] 
127. Kiryluk K, Julian BA, Wyatt RJ, et al. Genetic studies of IgA nephropathy: past, present, and 
future. Pediatric nephrology. 2010; 25:2257–68. [PubMed: 20386929] 
128. Yanagihara T, Brown R, Hall S, et al. generated immune complexes containing galactose-
deficient IgA1 stimulate proliferation of mesangial cells. Results in immunology. 2012; 2:166–
72. [PubMed: 24052934] 
129. Yanagawa H, Suzuki H, Suzuki Y, et al. A panel of serum biomarkers differentiates IgA 
nephropathy from other renal diseases. PloS one. 2014; 9:e98081. [PubMed: 24858067] 
130. Berthoux F, Suzuki H, Thibaudin L, et al. Autoantibodies targeting galactose-deficient IgA1 
associate with progression of IgA nephropathy. Journal of the American Society of Nephrology: 
JASN. 2012; 23:1579–87. [PubMed: 22904352] 
131. Berthelot L, Papista C, Maciel TT, et al. Transglutaminase is essential for IgA nephropathy 
development acting through IgA receptors. The Journal of experimental medicine. 2012; 
209:793–806. [PubMed: 22451718] 
132. Lorand L, Graham RM. Transglutaminases: crosslinking enzymes with pleiotropic functions. 
Nature reviews Molecular cell biology. 2003; 4:140–56. [PubMed: 12563291] 
133. Shweke N, Boulos N, Jouanneau C, et al. Tissue transglutaminase contributes to interstitial renal 
fibrosis by favoring accumulation of fibrillar collagen through TGF-beta activation and cell 
infiltration. The American journal of pathology. 2008; 173:631–42. [PubMed: 18688035] 
134. Fesus L, Piacentini M. Transglutaminase 2: an enigmatic enzyme with diverse functions. Trends 
in biochemical sciences. 2002; 27:534–9. [PubMed: 12368090] 
135. van Egmond M, van Vuuren AJ, Morton HC, et al. Human immunoglobulin A receptor 
(FcalphaRI, CD89) function in transgenic mice requires both FcR gamma chain and CR3 
(CD11b/CD18). Blood. 1999; 93:4387–94. [PubMed: 10361137] 
136. Van Spriel AB, Leusen JH, Vile H, Van De Winkel JG. Mac-1 (CD11b/CD18) as accessory 
molecule for Fc alpha R (CD89) binding of IgA. Journal of immunology. 2002; 169:3831–6.
Magistroni et al. Page 20
Kidney Int. Author manuscript; available in PMC 2016 May 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
137. Floege J, Moura IC, Daha MR. New insights into the pathogenesis of IgA nephropathy. Seminars 
in immunopathology. 2014; 36:431–42. [PubMed: 24442210] 
138. Matysiak-Budnik T, Moura IC, Arcos-Fajardo M, et al. Secretory IgA mediates retrotranscytosis 
of intact gliadin peptides via the transferrin receptor in celiac disease. The Journal of 
experimental medicine. 2008; 205:143–54. [PubMed: 18166587] 
139. Moura IC, Arcos-Fajardo M, Gdoura A, et al. Engagement of transferrin receptor by polymeric 
IgA1: evidence for a positive feedback loop involving increased receptor expression and 
mesangial cell proliferation in IgA nephropathy. Journal of the American Society of Nephrology: 
JASN. 2005; 16:2667–76. [PubMed: 15987753] 
140. Moura IC, Arcos-Fajardo M, Sadaka C, et al. Glycosylation and size of IgA1 are essential for 
interaction with mesangial transferrin receptor in IgA nephropathy. Journal of the American 
Society of Nephrology: JASN. 2004; 15:622–34. [PubMed: 14978164] 
141. Moura IC, Centelles MN, Arcos-Fajardo M, et al. Identification of the transferrin receptor as a 
novel immunoglobulin (Ig)A1 receptor and its enhanced expression on mesangial cells in IgA 
nephropathy. The Journal of experimental medicine. 2001; 194:417–25. [PubMed: 11514599] 
142. Novak J, Julian BA, Mestecky J, Renfrow MB. Glycosylation of IgA1 and pathogenesis of IgA 
nephropathy. Seminars in immunopathology. 2012; 34:365–82. [PubMed: 22434325] 
143. Lai KN. Pathogenesis of IgA nephropathy. Nature reviews Nephrology. 2012; 8:275–83. 
[PubMed: 22430056] 
144. Espinosa M, Ortega R, Sanchez M, et al. Association of C4d deposition with clinical outcomes in 
IgA nephropathy. Clinical journal of the American Society of Nephrology: CJASN. 2014; 9:897–
904. [PubMed: 24578331] 
145. Roos A, Rastaldi MP, Calvaresi N, et al. Glomerular activation of the lectin pathway of 
complement in IgA nephropathy is associated with more severe renal disease. Journal of the 
American Society of Nephrology: JASN. 2006; 17:1724–34. [PubMed: 16687629] 
146. Goicoechea de Jorge E, Caesar JJ, Malik TH, et al. Dimerization of complement factor H-related 
proteins modulates complement activation in vivo. Proc Natl Acad Sci U S A. 2013; 110:4685–
90. [PubMed: 23487775] 
147. Tortajada A, Yebenes H, Abarrategui-Garrido C, et al. C3 glomerulopathy-associated CFHR1 
mutation alters FHR oligomerization and complement regulation. The Journal of clinical 
investigation. 2013; 123:2434–46. [PubMed: 23728178] 
148. Zhu L, Zhai YL, Wang FM, et al. Variants in Complement Factor H and Complement Factor H-
Related Protein Genes, CFHR3 and CFHR1, Affect Complement Activation in IgA Nephropathy. 
Journal of the American Society of Nephrology: JASN. 2014
149. Hughes AE, Orr N, Esfandiary H, Diaz-Torres M, Goodship T, Chakravarthy U. A common CFH 
haplotype, with deletion of CFHR1 and CFHR3, is associated with lower risk of age-related 
macular degeneration. Nature genetics. 2006; 38:1173–7. [PubMed: 16998489] 
150. Zhao J, Wu H, Khosravi M, et al. Association of genetic variants in complement factor H and 
factor H-related genes with systemic lupus erythematosus susceptibility. PLoS genetics. 2011; 
7:e1002079. [PubMed: 21637784] 
151. Zipfel PF, Edey M, Heinen S, et al. Deletion of complement factor H-related genes CFHR1 and 
CFHR3 is associated with atypical hemolytic uremic syndrome. PLoS genetics. 2007; 3:e41. 
[PubMed: 17367211] 
152. Kidney Disease: Improving Global Outcomes (KDIGO) Glomerulonephritis Work Group. 
KDIGO Clinical Practice Guideline for Glomerulonephritis. Kidney inter, Suppl. 2012; 2:139–
274.
153. Coppo R, Peruzzi L, Amore A, et al. IgACE: a placebo-controlled, randomized trial of 
angiotensin-converting enzyme inhibitors in children and young people with IgA nephropathy 
and moderate proteinuria. Journal of the American Society of Nephrology: JASN. 2007; 
18:1880–8. [PubMed: 17513327] 
154. Li PK-T, Leung CB, Chow KM, et al. Hong Kong Study Using Valsartan in IgA Nephropathy 
(HKVIN): A Double-Blind, Randomized, Placebo-Controlled Study. American Journal of 
Kidney Diseases. 2006; 47:751–60. [PubMed: 16632013] 
Magistroni et al. Page 21
Kidney Int. Author manuscript; available in PMC 2016 May 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
155. Praga M, Gutierrez E, Gonzalez E, Morales E, Hernandez E. Treatment of IgA nephropathy with 
ACE inhibitors: a randomized and controlled trial. Journal of the American Society of 
Nephrology: JASN. 2003; 14:1578–83. [PubMed: 12761258] 
156. Horita Y, Tadokoro M, Taura K, et al. Prednisolone co-administered with losartan confers 
renoprotection in patients with IgA nephropathy. Renal failure. 2007; 29:441–6. [PubMed: 
17497466] 
157. Russo D, Pisani A, Balletta MM, et al. Additive antiproteinuric effect of converting enzyme 
inhibitor and losartan in normotensive patients with IgA nephropathy. American Journal of 
Kidney Diseases. 33:851–6.
158. CP, PGB, GBF, et al. Corticosteroids in IgA nephropathy: a randomised controlled trial. Lancet. 
1999
159. Pozzi C, Andrulli S, Del Vecchio L, et al. Corticosteroid effectiveness in IgA nephropathy: long-
term results of a randomized, controlled trial. Journal of the American Society of Nephrology: 
JASN. 2004; 15:157–63. [PubMed: 14694168] 
160. Manno C, Torres DD, Rossini M, Pesce F, Schena FP. Randomized controlled clinical trial of 
corticosteroids plus ACE-inhibitors with long-term follow-up in proteinuric IgA nephropathy. 
Nephrology, dialysis, transplantation: official publication of the European Dialysis and 
Transplant Association - European Renal Association. 2009; 24:3694–701.
161. Lv J, Xu D, Perkovic V, et al. Corticosteroid therapy in IgA nephropathy. Journal of the 
American Society of Nephrology: JASN. 2012; 23:1108–16. [PubMed: 22539830] 
162. Strippoli GF, Maione A, Schena FP, Tognoni G, Craig JC. IgA nephropathy: a disease in search 
of a large-scale clinical trial to reliably inform practice. American journal of kidney diseases: the 
official journal of the National Kidney Foundation. 2009; 53:5–8. [PubMed: 19101396] 
163. Komatsu H, Fujimoto S, Sato Y, et al. “Point of no return (PNR)” in progressive IgA 
nephropathy: significance of blood pressure and proteinuria management up to PNR. Journal of 
nephrology. 2005; 18:690–5. [PubMed: 16358226] 
164. Tang Z, Wu Y, Wang QW, et al. Idiopathic IgA nephropathy with diffuse crescent formation. 
American journal of nephrology. 2002; 22:480–6. [PubMed: 12381947] 
165. Abe T, Kida H, Yoshimura M, et al. Participation of extracapillary lesions (ECL) in progression 
of IgA nephropathy. Clinical nephrology. 1986; 25:37–41. [PubMed: 3955907] 
166. Tumlin JA, Lohavichan V, Hennigar R. Crescentic, proliferative IgA nephropathy: clinical and 
histological response to methylprednisolone and intravenous cyclophosphamide. Nephrology, 
dialysis, transplantation: official publication of the European Dialysis and Transplant Association 
- European Renal Association. 2003; 18:1321–9.
167. Stone JH, Merkel PA, Spiera R, et al. Rituximab versus cyclophosphamide for ANCA-associated 
vasculitis. The New England journal of medicine. 2010; 363:221–32. [PubMed: 20647199] 
168. Specks U, Merkel PA, Seo P, et al. Efficacy of remission-induction regimens for ANCA-
associated vasculitis. The New England journal of medicine. 2013; 369:417–27. [PubMed: 
23902481] 
169. Pozzi C, Andrulli S, Pani A, et al. Addition of azathioprine to corticosteroids does not benefit 
patients with IgA nephropathy. Journal of the American Society of Nephrology: JASN. 2010; 
21:1783–90. [PubMed: 20634300] 
170. Alamartine E, Sabatier JC, Berthoux FC. Comparison of pathological lesions on repeated renal 
biopsies in 73 patients with primary IgA glomerulonephritis: value of quantitative scoring and 
approach to final prognosis. Clinical nephrology. 1990; 34:45–51. [PubMed: 2225552] 
171. Schena FP. A retrospective analysis of the natural history of primary IgA nephropathy worldwide. 
The American journal of medicine. 1990; 89:209–15. [PubMed: 2200265] 
172. Xie J, Kiryluk K, Wang W, et al. Predicting progression of IgA nephropathy: new clinical 
progression risk score. PloS one. 2012; 7:e38904. [PubMed: 22719981] 
173. Coppo R, Troyanov S, Bellur S, et al. Validation of the Oxford classification of IgA nephropathy 
in cohorts with different presentations and treatments. Kidney Int. 2014
174. Magistroni R, Furci L, Leonelli M, et al. A validated model of disease progression in IgA 
nephropathy. Journal of nephrology. 2006; 19:32–40. [PubMed: 16523423] 
Magistroni et al. Page 22
Kidney Int. Author manuscript; available in PMC 2016 May 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
175. Koyama A, Igarashi M, Kobayashi M. Natural history and risk factors for immunoglobulin A 
nephropathy in Japan. Research Group on Progressive Renal Diseases. American journal of 
kidney diseases: the official journal of the National Kidney Foundation. 1997; 29:526–32. 
[PubMed: 9100040] 
176. Katafuchi R, Oh Y, Hori K, et al. An important role of glomerular segmental lesions on 
progression of IgA nephropathy: a multivariate analysis. Clinical nephrology. 1994; 41:191–8. 
[PubMed: 8026110] 
177. Okada H, Suzuki H, Konishi K, Sakaguchi H, Saruta T. Histological alterations in renal 
specimens as indicators of prognosis of IgA nephropathy. Clinical nephrology. 1992; 37:235–8. 
[PubMed: 1606773] 
178. D’Amico G. Natural history of idiopathic IgA nephropathy: role of clinical and histological 
prognostic factors. American journal of kidney diseases: the official journal of the National 
Kidney Foundation. 2000; 36:227–37. [PubMed: 10922300] 
179. Smerud HK, Barany P, Lindstrom K, et al. New treatment for IgA nephropathy: enteric 
budesonide targeted to the ileocecal region ameliorates proteinuria. Nephrology, dialysis, 
transplantation: official publication of the European Dialysis and Transplant Association - 
European Renal Association. 2011; 26:3237–42.
180. Beecham AH, Patsopoulos NA, et al. International Multiple Sclerosis Genetics C. Analysis of 
immune-related loci identifies 48 new susceptibility variants for multiple sclerosis. Nat Genet. 
2013; 45:1353–60. [PubMed: 24076602] 
181. Visscher PM, Brown MA, McCarthy MI, Yang J. Five years of GWAS discovery. American 
journal of human genetics. 2012; 90:7–24. [PubMed: 22243964] 
182. Visekruna A, Joeris T, Seidel D, et al. Proteasome-mediated degradation of IkappaBalpha and 
processing of p105 in Crohn disease and ulcerative colitis. The Journal of clinical investigation. 
2006; 116:3195–203. [PubMed: 17124531] 
183. Wu F, Dassopoulos T, Cope L, et al. Genome-wide gene expression differences in Crohn’s 
disease and ulcerative colitis from endoscopic pinch biopsies: insights into distinctive 
pathogenesis. Inflammatory bowel diseases. 2007; 13:807–21. [PubMed: 17262812] 
184. Schmidt N, Gonzalez E, Visekruna A, et al. Targeting the proteasome: partial inhibition of the 
proteasome by bortezomib or deletion of the immunosubunit LMP7 attenuates experimental 
colitis. Gut. 2010; 59:896–906. [PubMed: 20581238] 
185. Fujimoto K, Karuppuchamy T, Takemura N, et al. A new subset of CD103+CD8alpha+ dendritic 
cells in the small intestine expresses TLR3, TLR7, and TLR9 and induces Th1 response and CTL 
activity. Journal of immunology. 2011; 186:6287–95.
186. Uematsu S, Fujimoto K, Jang MH, et al. Regulation of humoral and cellular gut immunity by 
lamina propria dendritic cells expressing Toll-like receptor 5. Nature immunology. 2008; 9:769–
76. [PubMed: 18516037] 
187. Hom G, Graham RR, Modrek B, et al. Association of systemic lupus erythematosus with 
C8orf13-BLK and ITGAM-ITGAX. The New England journal of medicine. 2008; 358:900–9. 
[PubMed: 18204098] 
188. Bertin J, Guo Y, Wang L, et al. CARD9 is a novel caspase recruitment domain-containing protein 
that interacts with BCL10/CLAP and activates NF-kappa B. The Journal of biological chemistry. 
2000; 275:41082–6. [PubMed: 11053425] 
189. Sokol H, Conway KL, Zhang M, et al. Card9 mediates intestinal epithelial cell restitution, T-
helper 17 responses, and control of bacterial infection in mice. Gastroenterology. 2013; 145:591–
601. e3. [PubMed: 23732773] 
190. Beaudoin M, Goyette P, Boucher G, et al. Deep resequencing of GWAS loci identifies rare 
variants in CARD9, IL23R and RNF186 that are associated with ulcerative colitis. PLoS 
genetics. 2013; 9:e1003723. [PubMed: 24068945] 
191. Rivas MA, Beaudoin M, Gardet A, et al. Deep resequencing of GWAS loci identifies independent 
rare variants associated with inflammatory bowel disease. Nature genetics. 2011; 43:1066–73. 
[PubMed: 21983784] 
192. Lanternier F, Pathan S, Vincent QB, et al. Deep dermatophytosis and inherited CARD9 
deficiency. The New England journal of medicine. 2013; 369:1704–14. [PubMed: 24131138] 
Magistroni et al. Page 23
Kidney Int. Author manuscript; available in PMC 2016 May 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
193. Vigorito E, Gambardella L, Colucci F, McAdam S, Turner M. Vav proteins regulate peripheral B-
cell survival. Blood. 2005; 106:2391–8. [PubMed: 15941910] 
194. Liu JY, Seno H, Miletic AV, Mills JC, Swat W, Stappenbeck TS. Vav proteins are necessary for 
correct differentiation of mouse cecal and colonic enterocytes. Journal of cell science. 2009; 
122:324–34. [PubMed: 19139088] 
195. Levison SE, Fisher P, Hankinson J, et al. Genetic analysis of the Trichuris muris-induced model 
of colitis reveals QTL overlap and a novel gene cluster for establishing colonic inflammation. 
BMC genomics. 2013; 14:127. [PubMed: 23442222] 
196. Eriksson N, Tung JY, Kiefer AK, et al. Novel associations for hypothyroidism include known 
autoimmune risk loci. PloS one. 2012; 7:e34442. [PubMed: 22493691] 
197. Litinskiy MB, Nardelli B, Hilbert DM, et al. DCs induce CD40-independent immunoglobulin 
class switching through BLyS and APRIL. Nature immunology. 2002; 3:822–9. [PubMed: 
12154359] 
198. Osman W, Okada Y, Kamatani Y, Kubo M, Matsuda K, Nakamura Y. Association of common 
variants in TNFRSF13B, TNFSF13, and ANXA3 with serum levels of non-albumin protein and 
immunoglobulin isotypes in Japanese. PloS one. 2012; 7:e32683. [PubMed: 22558069] 
199. Castigli E, Wilson SA, Garibyan L, et al. TACI is mutant in common variable immunodeficiency 
and IgA deficiency. Nature genetics. 2005; 37:829–34. [PubMed: 16007086] 
200. Kalabis J, Patterson MJ, Enders GH, et al. Stimulation of human colonic epithelial cells by 
leukemia inhibitory factor is dependent on collagen-embedded fibroblasts in organotypic culture. 
FASEB journal: official publication of the Federation of American Societies for Experimental 
Biology. 2003; 17:1115–7. [PubMed: 12692084] 
201. Ernst M, Inglese M, Waring P, et al. Defective gp130-mediated signal transducer and activator of 
transcription (STAT) signaling results in degenerative joint disease, gastrointestinal ulceration, 
and failure of uterine implantation. The Journal of experimental medicine. 2001; 194:189–203. 
[PubMed: 11457894] 
Magistroni et al. Page 24
Kidney Int. Author manuscript; available in PMC 2016 May 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Figure 1. Pathologic features of IgA nephropathy by light microscopy, immunofluorescence and 
electron microscopy
(a) The glomerulus has global mesangial proliferation with at least 4 cells per mesangial 
area. When >50% of glomeruli exhibit mesangial hypercellularity, the biopsy receives a 
score of M1 according to the Oxford/IgA MEST system (H&E, x600).
(b) Segmental endocapillary proliferation obliterates capillary lumina (score E1 when a 
biopsy contains one or more such lesions). The adjacent glomerular segments have mild 
mesangial hypercellularity (H&E, x600).
(c) The stain for IgA is intense and globally outlines the mesangial framework of the 
glomerulus (immunofluorecence, x600).
(d) Segmental glomerular scarring develops as postinflammatory sclerosis, mimicking the 
changes in focal segmental glomerulosclerosis. (score S1 when a biopsy contains one or 
more such lesions), (Jones methenamine silver, x600).
(e) A case with high chronicity contains globally sclerotic glomeruli and exhibits more than 
50% tubular atrophy/interstitial fibrosis (score T2), (Masson trichrome, x200).
(f) The immunofluorescence staining for C3 is similar in distribution as the mesangial 
staining for IgA (shown from the same glomerulus as in 1C) but exhibits weaker intensity 
and a more punctate, granular texture (immunofluorescence, x600).
(g) A severe example has a cellular crescent that compresses the glomerular tuft. Global 
mesangial expansion is present (Jones methenamine silver, x400).
(h) One or more red blood cell casts are commonly encountered at biopsy and may be 
numerous, especially in cases with gross hematuria and acute tubular injury (H&E, x600).
(i) By electron microscopy, large mesangial deposits elevate the glomerular basement 
membrane reflection over the mesangium, bulging towards the urinary space. This deposit 
involves the entire mesangium but is most prominent in the paramesangial region, beneath 
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the GBM reflection. The mesangial cellularity is increased but the capillary lumen is patent 
(electron micrograph, x5000).
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Figure 2. Geospatial Pattern of Genetic Risk for IgA Nephropathy and Worldwide Map of 
Helminth Diversity
Top Panel: Surface interpolation of the standardized genetic risk over Africa and Euroasia. 
Symbols represent the locations of sampled populations: Human Genome Diversity Panel 
(HGDP; 1,050 individuals representative of 52 worldwide populations), HapMap III (1,184 
individuals representative of 11 populations), other population samples (4,547 individuals 
representative of 25 populations); from Kiryluk et al. PLoS Genetics 2012;8(6):e1002765.
Bottom Panel: Standardized values for the diversity of helminth species infecting humans 
per country; data from the Global Infectious Disease and Epidemiology Online Network 
(GIDEON), see URL.
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Figure 3. 
The Multi-hit Pathogenesis Model of IgA Nephropathy.
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Figure 4. Genetic Hits to the “Intestinal Immune Network for IgA Production”
IgA is the most abundant antibody isotype in the body, with the majority of IgA found in 
mucosal secretions. Mucosal IgA production is induced by T cell-dependent and T cell-
independent mechanisms. T cell-independent production of IgA is primarily stimulated by 
IL-6, IL-10, TGF-β, BAFF, and APRIL produced by intestinal epithelial, dendritic, and 
stromal cells. In this environment, intestinal B cells undergo class switching from IgM to 
IgA1. IgA-secreting plasma cells migrate to lamina propria, where they release dimeric 
IgA1. The dimers are formed through an interaction of two IgA1 molecules with a joining 
chain (J-chain), which is synthesized by plasma cells. IgA1 dimers can bind to the polymeric 
Ig receptor (pIgR) on the basolateral surface of the mucosal epithelium and undergo 
transcytosis to the apical surface, where they dissociate from pIgR and are secreted into the 
lumen carrying the secretory component of the receptor. The secretory component protects 
IgA molecules from proteolytic enzymes in the gut lumen. The bacteriostatic effects of 
secretory IgA1 are accompanied by antimicrobial peptides, such as defensins, secreted into 
the gut lumen by Paneth cells. The key molecules involved in the intestinal immune network 
for IgA production are indicated in orange; molecules implicated by GWAS are marked in 
red. The risk alleles generally lead to increased IgA1 responsiveness stimulating IgA1 
production; increased levels of polymeric IgA1 in the circulation may represent a 
consequence of “spill-over” from mucosal sites and/or “mis-trafficking” of stimulated 
plasma cell to bone marrow sites.
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Table 1
Summary of IgAN GWAS loci, their functions, pleiotropic effects, and potential role in the pathogenesis of 
IgAN.
GWAS Candidate Genes Structure, Function, and Gene Expression
Potential Relationship to 
the Multi-hit 
Pathogenesis Model
Pleiotropic Effects and Links 
to Other Immune- mediated 
Diseases
HLA-DQA1, HLA-DQB1, HLA-DRB1, • MHC class II 
molecules are critical 
for antigen 
presentation and 
adaptive immunity
• There are four 
independent classical 
HLA alleles 
associated with IgAN 
at this locus; two risk 
alleles (DQA1*0101, 
DQB1*0301) and 
two protective alleles 
(DQA1*0102, 
DQB1*0201).
• MHC-II 
molecules 
participate in 
the regulation 
of intestinal 
inflammation 
and IgA 
production 
(may 
contribute to 
Hit 1).
• Some class II 
alleles have a 
permissive role 
in 
autoimmunity, 
thus may be 
associated with 
a greater risk 
of anti- glycan 
response (Hit 
2).
• Concordant effect 
on the risk of 
rheumatoid arthritis, 
systemic sclerosis, 
alopecia areata, 
Graves’ disease, 
follicular 
lymphoma, type I 
diabetes, Celiac 
disease, and IgA 
deficiency.
• Opposed effect on 
the risk of SLE, 
multiple sclerosis, 
ulcerative colitis, 
and hepatocellular 
carcinoma.
HLA-DP • MHC class II 
molecules, less well 
studied compared to 
HLA-DQ and HLA-
DR.
• May contribute 
to either Hit 1 
or Hit 2, 
(similar to 
above).
• This locus has been 
previously 
associated with 
systemic sclerosis, 
ANCA vasculitis, 
Graves’ disease and 
HBV infection, but 
it is not clear if the 
IgAN risk allele has 
any effect on these 
traits.
TAP2, PSMB8, PSMB9 • The IgAN signal at 
this locus is specific 
to Asians.
• PSMB8 and PSMB9 
are interferon-
induced subunits of 
the 
immunoproteosome 
that mediate 
intestinal NF-κB 
activation in IBD182.
• PSMB8 is up 
regulated in intestinal 
tissue with active 
IBD lesions183. 
Treatment with 
bortezomib (PSMB8 
inhibitor) attenuates 
experimental 
colitis184.
• The risk allele 
represents a 
cis-eQTL 
associated with 
increased 
peripheral 
blood 
expression of 
TAP2, PSMB8 
and PSMB9, 
which may 
result in a pro- 
inflammatory 
state 
modulating Hit 
1 through up 
regulation of 
intestinal 
inflammation.
• This locus has been 
previously 
associated with 
Kawasaki disease, 
degenerative disc 
disease, and 
lymphoma, but it is 
not clear if the 
IgAN risk allele has 
any effect on these 
traits.
CFHR1, CFHR3 • Common deletion of 
CFHR1 and 3 genes 
• Modulates 
local 
complement 
activation in 
• Concordant 
(protective) effect 
on the risk of age-
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GWAS Candidate Genes Structure, Function, and Gene Expression
Potential Relationship to 
the Multi-hit 
Pathogenesis Model
Pleiotropic Effects and Links 
to Other Immune- mediated 
Diseases
has a protective 
effect against IgAN.
• CFHR1 and 3 genes 
encode Factor H-
related peptides that 
modulate the activity 
of the alternative 
complement 
pathway. FHR1 
competes with FH 
for binding to 
surface-fixed C3b 
leading to increased 
activation of C3 
convertase146.
the kidney (Hit 
4); protective 
deletion of 
CFHR1 and 
CFHR3 is 
associated with 
higher 
circulating 
levels of Factor 
H and 
dampened 
local activation 
of the 
alternative 
complement 
pathway148.
related macular 
degeneration.
• Opposed (risk) 
effect on the risk of 
SLE and atypical 
HUS due to anti-FH 
antibodies.
ITGAM, ITGAX • ITGAM and ITGAX 
encode integrins αM 
and αX that combine 
with integrin β2 
chain to form 
leukocyte- specific 
complement 
receptors 3 and 4 
(CR3 and CR4, 
respectively).
• Intestinal dendritic 
cells that induce T-
cell-independent IgA 
class-switch 
recombination 
express high levels of 
αM and αX 
integrins185,186. 
ITGAM and ITGAX 
are also expressed in 
macrophages and 
participate in the 
process of 
phagocytosis.
• CR3 and CR4 
may play a role 
in the 
regulation of 
glomerular 
inflammation 
(Hit 4), 
including 
phagocytosis 
of 
complement-
coated immune 
complexes
• αM and αX 
integrins are 
involved in the 
regulation of 
intestinal 
inflammation 
and IgA 
production, 
thus may be 
involved in Hit 
1.
• There are at least 
two independent 
risk alleles at this 
locus; one of the 
alleles is fixed in 
Asians. This allele 
has an opposed 
effect on the risk of 
SLE187.
CARD9 • CARD9 encodes a 
molecular scaffold 
for the assembly of a 
BCL10 signaling 
complex that 
activates NF-κB, 
which is responsible 
for both innate and 
adaptive immune 
responses188.
• CARD9 is a pro-
inflammatory 
molecule, and the 
IgAN risk allele is 
strongly associated 
with its increased 
expression (cis-eQTL 
effect).
• CARD9 mediates 
intestinal repair, T-
helper 17 responses, 
and control of 
bacterial infection 
after intestinal 
• Potentially 
modulates Hit 
1 through 
regulation of 
intestinal 
inflammation 
and IgA 
production.
• The IgAN risk 
allele increases 
CARD9 expression 
and has a 
concordant effect on 
the risk of IBD.
• Conversely, a rare 
protein-truncating 
splice variant in 
CARD9 confers 
additive protection 
from IBD190,191, but 
its effect on the risk 
of IgAN has not 
been tested.
• Familial CARD9 
deficiency 
predisposes to 
invasive fungal 
infections192.
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Potential Relationship to 
the Multi-hit 
Pathogenesis Model
Pleiotropic Effects and Links 
to Other Immune- mediated 
Diseases
epithelial injury in 
mice189.
VAV3 • VAV proteins are 
guanine nucleotide 
exchange factors 
essential for adaptive 
immune function and 
NF-κB activation in 
B-cells, a process 
that stimulates IgA 
production193.
• VAV proteins are 
required for proper 
differentiation of 
colonic enterocytes 
and preventing 
spontaneous 
ulcerations of 
intestinal mucosa194.
• VAV proteins are 
also expressed in 
macrophages and 
participate in 
phagocytosis.
• Potentially 
modulates Hit 
1 through 
regulation of 
intestinal 
inflammation 
and IgA 
production.
• May also 
modulate Hit 4 
through 
regulation of 
glomerular 
inflammation, 
phagocytosis, 
and clearance 
of immune 
complexes.
• VAV3 is a positional 
candidate for QTL 
for mouse intestinal 
inflammation in a 
parasite- induced 
(Trichuris muris) 
model-of 
infection195.
• A common variant 
in VAV3 has 
previously been 
associated with 
autoimmune 
hypothyroidism196, 
however, the IgAN 
signal represents an 
independent 
association.
DEFA1, DEFA3, DEFA5, DEFA6 • α-defensins are 
antimicrobial 
peptides that provide 
innate defense 
against microbial 
pathogens.
• α-defensin 1 and 3 
are synthesized in 
neutrophils. DEFA1 
and DEFA3 genes 
are prone to complex 
copy number 
variation with a gene 
copy correlating with 
the expression level 
of these peptides.
• α-defensin 5 and 6 
(DEFA5 and DEFA6) 
are constitutively 
produced by the 
intestinal Paneth 
cells.
• It is not clear if 
the IgAN risk 
allele tags a 
risk haplotype 
carrying a 
specific copy 
number of 
DEFA1/3 
genes, or if the 
association is 
due to variants 
in the nearby 
intestinally-
expressed 
DEFA5 or 
DEFA6 genes.
• This locus may 
potentially 
modulate Hit 1 
through 
regulation of 
intestinal 
microbial 
pathogens and 
inflammation.
• Deficiencies in α-
defensins-5 and -6 
have been 
previously 
associated with 
Crohn’s disease.
TNFSF13 • TNFSF13 encodes 
APRIL, a powerful 
B-cell stimulating 
cytokine that is 
induced by intestinal 
bacteria and 
promotes CD40-
independent IgA 
class switching197.
• APRIL levels are 
elevated in patients 
with IgAN115 and the 
IgAN risk allele is 
associated with 
• Potentially 
modulates Hit 
1 through 
direct up-
regulation of 
intestinal IgA 
production.
• IgAN risk allele has 
been associated 
with elevated serum 
non-albumin protein 
and IgA levels 198.
• Mutations in the 
TNFSF13 receptor 
(TACI) produce 
IgA deficiency or 
combined variable 
immunodeficiency, 
with increased 
propensity to 
Kidney Int. Author manuscript; available in PMC 2016 May 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Magistroni et al. Page 33
GWAS Candidate Genes Structure, Function, and Gene Expression
Potential Relationship to 
the Multi-hit 
Pathogenesis Model
Pleiotropic Effects and Links 
to Other Immune- mediated 
Diseases
increased IgA 
levels86.
mucosal 
infections199
LIF, OSM, HORMAD2, MTMR3 • LIF and OSM 
represent the top 
positional candidates; 
both are IL-6 related 
cytokines that use 
gp130 for signal 
transduction and 
have been previously 
implicated in 
mucosal immunity.
• LIF is secreted by 
pericrypt fibroblasts 
and may be critical 
for proliferation and 
renewal of 
enterocytes200.
• Genetic disruption of 
gp130 signaling leads 
to gastrointestinal 
ulceration and 
inflammatory joint 
disease in mice201.
• Potentially 
modulates Hit 
1 through 
direct up-
regulation of 
intestinal IgA 
production.
• The IgAN risk 
allele at this locus is 
protective against 
Crohn’s disease and 
associated with 
increased serum 
IgA levels85.
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lit
y
Fi
sh
 o
ils
Fi
sh
 o
ils
 m
ay
 b
e 
po
te
nt
ia
lly
 u
se
fu
l i
n 
pa
tie
nt
s w
ith
 p
er
sis
te
nt
 
pr
ot
ei
nu
ria
 ≥
 1
g/
d,
 d
es
pi
te
 3
–6
-m
on
th
s o
f o
pt
im
iz
ed
 
su
pp
or
tiv
e 
ca
re
.
2D
R
CT
s g
iv
e 
eq
ui
vo
ca
l r
es
ul
ts 
on
 th
e 
be
ne
fit
 o
f f
ish
 o
ils
. G
iv
en
 lo
w
 si
de
 e
ffe
ct
 
pr
of
ile
 a
nd
 o
ve
r-t
he
-c
ou
nt
er
 a
va
ila
bi
lit
y,
 th
e 
us
e 
of
 fi
sh
 o
ils
 c
an
 p
ro
ba
bl
y 
be
 
le
ft 
to
 th
e 
ch
oi
ce
 o
f i
nd
iv
id
ua
l p
at
ie
nt
s. 
H
ow
ev
er
, t
hi
s t
re
at
m
en
t s
ho
ul
d 
no
t 
re
pl
ac
e 
co
rti
co
ste
ro
id
s, 
fo
r w
hi
ch
 th
e 
ev
id
en
ce
 is
 st
ro
ng
er
.
To
ns
ill
ec
to
m
y
N
ot
 re
co
m
m
en
de
d
2C
N
o 
co
nv
in
ci
ng
 e
vi
de
nc
e 
of
 b
en
ef
it.
 G
en
er
al
ly
 n
ot
 re
co
m
m
en
de
d,
 u
nl
es
s 
sp
ec
ifi
ca
lly
 in
di
ca
te
d 
by
 re
cu
rre
nt
 e
pi
so
de
s o
f t
on
sil
lit
is 
w
ith
 sy
np
ha
ry
ng
iti
c 
di
se
as
e 
fla
re
s.
R
ec
om
m
en
da
tio
n 
gr
ad
in
g:
 L
ev
el
 1
 =
 “
Re
co
m
m
en
de
d”
, L
ev
el
 2
 =
 “
Su
gg
es
te
d”
. Q
ua
lity
 of
 ev
ide
nc
e g
rad
ing
: A
 = 
“H
igh
”, 
B 
= “
M
od
era
te”
, C
 = 
“L
ow
”, 
D 
= “
Ve
ry 
Lo
w”
.
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